Journal of Gastroenterology and Hepatology (2002) **17**, 1349–1355

Author Index to Volume 17

Abbas Z 577
Abbott CA 66
Abi-Hanna D 215
Abo T 81
Abraldes S232
Acharya SK S268
Adachi M 27, 606
Adams DH 116
Agarwal A S294
Aggarwal R 1331
Ahmed I 270, 1267
Akahoshi T 59, 77
Akaike M 1110
Akanuma M 556, 1244
Akashi Y 925
Akatsuka T 897
Akdogan M 72
Alavian SM 1092
Al-Jiffry BO 324
Amarsanaa J 556, 1244
Ammatuna E 1039
Andoh A 818, 854
Ang TL 908
Angulo P 196, S186
Angus PW 733, 737
Anselmi K 589
Apte M 177, 1045
Arai M 625
Arakawa M 1064
Arya G 521
Asakura H 81
Attard 1342
Ayyagari A 1331
Azuma T 262

Bacon BR 785
Badur S 72
Balistreri WF 521
Bamba T 818, 854
Banerjee M 1161
Bariol C 135
Barrière E 882, 1106
Bartholomeusz A 442
Baskaran V 1344
Bassett ML 800
Bassi C S15
Batra Y S268
Bernuau J 882
Berthillon P S460
Beuers U 938
Bhathal P 236
Bhave SA S403
Billig H 713
Bindley P 171
Bines JE 1170
Biswas PK 183
Blakely TA 582
Blum HE S306, S399, S413
Blumberg BS S502
Boey CC-M 1250
Bonser R 208
Borén J 713
Bosch J S232
Bosnak M 1087
Bosnak V 1087
Britton RS 785
Brokke-Smith MS S15
Brown KE 785
Brown SJ 110
Brunton CR 582
Buckels J 208
Butler WJ 177
Butterworth L 889
Burkov A S360
Byrnes DJ 135
Byth K 873

Calne RY S488
Calza L 1342
Carayon A 1106
Carlsson B 713
Carlsson LMS 713
Carr-Locke D S15, S50
Carr-Locke DL 1323
Carroccio A 1039
Castegnaro J-J S441
Catto-Smith A 1170
Cavanaugh JA 800
Chadwick VS 987
Chah TK S421
Chairman SO 127
Chan C-K 1323
Chan CK 1272
Chan H-H 337
Chan JKF 1323
Chan RC 933
Chan Y-K 1180
Chang C-S 46
Chang F-Y 1187, 1254
Chang HY S329
Chang L-Y 1220
Chang R 690
Chang T-T 682
Chang W-Y 190, 682, 1192
Chang Y-T 724
Chang YW 690
Changchien C-S 682, 1307
Chatchatee P S155
Chauhan R S311
Chawla Y 6
Chayama K 949
Chen C-H 682, 1307
Chen C-Y 1254
Chen D-S 682
Chen DS S40
Chen G-H 46, 682, 1015
Chen H 659
Chen J-H 1220
Chen RYM S471
Chen S-C 190 682, 1192
Chen T-M 1307
Chen W 987
Chen WN S491, S497
Chen YY 682
Cheng J S342
Cheng J-S 337
Cheng T-I 1239
Cheng YC S460
Cheung KL 1272
Cheung ST 1008
Chiang G S491
Chiodo F 1342
Chitti LD 103, 622
Cho Y-K 253
Choe YH 131
Choi C-H 32
Choi KD 754
Choi S-M 32
Choi W-B 52
Chongsrisawat V S155
Choudhury V S268
Chow KC 834
Chow WC 148
Chua TS 908
Chuang VP 1239
Chuang W-L 190, 1192
Chung S 355
Chung Y-H 52, 345
Chutaputti A 456, 671, S40
Cirrincione S 1039
Cjap W S50
Clark C 1161
Claydon M 1329
Coia J 1161
Colle I 882, 1106
Condat B 1106, S224
Consensus Study Group 508
Cooksley G 889
Cornberg M S344
Crowley S 153
Cummins AG 1130

Dacosta RS S85
Dagli A 1087
Dai C-Y 1192
Dan Y S40
Daniele B S40
Das D 183

Dattagupta S S268
Davaris PS 1084
Day CP S377
De BK 183
De Boer WB 203
De Cantis S 1039
de Franchis R S242
De Man RA S338
Deguchi Y 1119
Dehpour AR 96
Dent J 825
Desmond P 153
Desmond PV S471
Dev A 295
Dhiman RK 6
Di Trapani R 1039
Diallo MS S441
Dickinson RG 66
Dickson ER 196
Dikici B 1087
Dilawari JB 6
Donaghy A 462
Dong SH 690
Dong Y 1299
Donnelly MT 723
Dore GJ 423
Du J-M 682
Dupont HL S54
Durand F 882

Ebihara Y 966
Ece A 1087
Edwards PD 135
Egawa I 1098
Egberts E-H 677
Elias E 208
Ellem K 889
Ely SA 226
Emselle S 1170
Endo R 140
Endo Y 1198
Erdem L 72
Esumi H 308

Fan ST 1008
Fang D-C 1144
Farrell GC 353, 873
Farthing M S54
Ferenci P S105
Ferguson J 203
Field A 135
Fielding G 889
Fields HA S360
Fock KM 908
Forbes GM 127
Fox JG 495
Freeman AJ 423
Freeny P S15
Frenzer A 177
Fujii M 1242
Fujisawa T 617
Fujiwara K 285, K 625
Fujiyama Y 818, 854
Fukami N 382
Fukuda S 1278
Fuller PJ 1170
Funaki N 1198
Funakoshi S 105
Furuta S 1283

Gamo N 925
Gandh CR 589
Garas G 203
Garg PK 508
George J 873
Germon S S460
Gershwin ME 308
Ghabrial H 598
Gholami B 1092
Ghosh S 1161
Ghoshal U 1331
Ghoshal UC 1331
Gibson P 236
Glasova H 938
Glise H S72
Gluseska S 171
Gobé GC 966
Goddard S 116
Goh KL 281, 482, 1250
Goh KT S491
Gonsalvez C 171
Goo KS S491
Gopalakrishnan V S370
Gorrell MD 66
Gotley D 825
Goto H 1283
Gotoh N 59, 77
Gotoh Y 332
Govil S 1117
Gow PJ 733
Grannell M S172
Grimm MC 935
Gunawan E 960
Gupta S S287
Guptan RC 165, 765
Gur U 208

Haber J 196
Haga S 227
Hagino Y 807
Hagiwara C 758
Hahm K-B 253
Haites N 1161
Hall AJ S441
Hamashima C 571
Hamid S 577
Han J-M 345
Han K-H S329, S424
Han S-U 253
Han YS 690
Hanafusa T 285
Hanazaki K 1229
Harada K 217, 1334
Hardikar W 476
Hari R S370
Hartland EL 467
Haruma K 949
Hashimoto N 1198
Hashizume M 59, 77
Haspolat K 1087
Hasumi K 651
Hata K 854
Hattori T 262
Häussinger D S256, S260
Hayakawa T 1283
Hayashi H 91, 806, 811
Hayashi N 772
Hayashi S 1198
Hayashida K 1098
Hayashida N 1198
Hazama H 316, 1098
Hazari S S268
Heath D 203
Heckmann C 791
Heller J 1106
Herath NI 301
Hibi T 105
Higashi T 285
Higashihara H 728
Higashizawa T 332
Hilleman MR S449
Hilzenrat N 1317
Hing M 135
Hinze S 677
Hirano T 1070
Hirasawa H 625
Hirata Y 556, 1244
Hirota S 659
Hiyama T 226
Hoffmann NE 276
Hokari A 308
Hollinshead J 1033
Holloway R 825
Holstein A 677
Homayoun H 96
Hong YC 131
Hongo M S1
Hori M 960
Hori T 1070
Horie Y 606, 1240
Hoshino K 1211
Hou C 1192
Houghton J 495
House AK 203
Howard CR S464, S468
Hsieh M-Y 190, 1192
Hsu P-I 337
Hu H 973
Hu WH-C 1180
Hu WHC 545, 1272, 1323
Huang J-F 190, 1192
Huang S-P 1165, 1220
Huang Y-H 1187
Huang Y-S 1187
Hughes L 1033
Hui CK 1001
Hui JM 873
Hui WM 545
Hung C-H 1307

Huo T-I 1187
Hurlstone DP 623, 633, 723, 929, 1345
Hwang TS 131

Iannitto E 1039
Ichida T 81
Ichijo T 813
Ichijou T 1229
Ido K 332
Iimuro Y 1119
Iishi H 955
Iizuka M 1240
Ikai I 1119
Ikeda M 955, 1205
Ikeda Y 1198
Ikenoue T 556, 1244
Imada T 1110
Imai Y 708
Imamura M 854
Imrie C S15
Inaba T 27, 748
Inamori M 1291
Inoh M 925
Inokuchi H 262
Inoue H 382
Inui A 617
Ip YC 1008
Irie Y 91
Ishihara M 1119
Ishii H 105, 606
Ishii HK 966
Ishikawa T 81
Ishiki K 27
Isomoto H 1098
Isozaki A 617
Isozaki K 659
Itani-Yohda T 897
Ito M 1260
Ito S 1021
Itoh Y 806, 811
Iwabuchi S 1198
Iwaki K 807
Iwamoto S 104, 1330, 1340
Iwane S 1278
Iwao Y 105
Iwasa Y 1119
Iwata R 779

Jaggi R 66
Jain M 1331
Jang TJ 839
Janssen HLA S338
Jass JR 17
Jayaram S S370
Jayasuriya R 171
Jeffrey GP 203
Jeon H-J 32
Jeyakumar P S370
Jiang K 1299
Johnson MSC 713
Joo H-J 253
Jorgensen R 196
Jung S 345
Justice F 1170

Kachi M 1242
Kadokawa Y 1098
Kadota T 1098
Kaffes A 1033
Kajikawa S 1229
Kajiwara T 227
Kakkar N 6
Kako M 1198
Kaldor JM 423
Kamath PS S253, S298
Kameda Y 1110
Kamili S S365
Kamiya K 1283
Kanauchi O 818
Kanayama S 1040
Kanda T 625, 955
Kaneko A 955
Kang Y-H 563
Kanno J 1078
Kano K 844
Kao J-H 113, 643
Kapoor D 526, S280, S482
Karegeh MA 929
Kashima T 91
Kashio S 955
Kashiwagi K 105
Kataoka M 535
Katayanagi K 217
Katelaris P 825, 1033
Kathayat R 1312
Kato H 227, 671
Kato S 606
Katz G 196
Kavantzas N 1084
Kawabe T 308
Kawaguchi J 861
Kawai K 262, 748
Kawano K 807
Kawano S 955, 960
Kazim SN 165, 765
Kellow J S1
Kellow JE 503
Kelly D 208
Kench J 873
Kew MC 301
Khan NA 785
Khudyakov YE S360
Kim B-H 690
Kim D-Y 253
Kim EJ 563
Kim EK 914
Kim HJ 690
Kim K-H S329
Kim K-J 32
Kim M-W 253
Kim NI 839
Kim WS 914
Kim Y-B 253
Kimber R 343
Kimber RD 621
Kimmoun E S408
Kimura A 960
Kimura S 394
Kinoshita H 316
Kinoshita K 659
Kircheis G S256, S260
Kitajima M 1211
Kitano S 807
Kiyohara T 659
Kiyosawa K 813, 1229
Ko C-W 46
Ko JS 754
Kobayashi S 91, 227
Kobayashi Y 844
Koga Y 651
Koh S S491
Kohno S 316, 1098
Koike K 394
Kojima H 625
Kojiro M 994
Komatsu H 617
Kondo S 1040
Kong G 914
Kon-no S 1240
Koo MW-L 552
Korulla C 1345
Kositchaiwat C S54
Krawczynski K S365
Kubo M 925, 955
Kubota Y 708
Kudo H 758
Kudo S-E 382
Kumar A 1331
Kumazawa K 227
Kuo C-H 682
Kuo M-L 1165
Kurata N 925
Kurimoto M 285
Kuriyama H 1205
Kurumaya H 217
Kwan AC-P 1180
Kwon Y 345

Ladhams A 889
Lai CL 1001, S510
Lai K-C 294, 545, 1323
Lai KC 834, 1001, 1272
Lai K-H 337
Lai TS-T 1180
Lam CLK 545
Lam K-F 545
Lam S-K 294, 545, 1323
Lam SK 834, 1001 1272, S510
Langlet P 1106
Lavanchy DL S452
Law M 423
Law S 374
Lazaris AC 1084
Le Guerhier F S460
Lebrec D 882, 1106, S224
Lee C-C 1015
Lee C-M 1307
Lee HC 345

Lee JI 690
Lee JK 52, 914
Lee JT S424
Lee KT 914
Lee S-D 1187, 1254
Lee T-B 32
Lee W-H 253
Lee Y-C 1220
Lee Y-J 345
Lee YS 52, 345
Lee YW 914
Leelakusolvong S S54
Lees M 153
Leggett B 389, 889
Leggett BA 17, 301
Leong AL S491
Lessels A 1161
Leung N 409
Leung NWY S146
Leung SY 834
Li D 987
Li L 1299
Liang G-P 1144
Liao L-Y 682
Liaw Y-F 406, 682, S333
Liddle C 873
Lien H-C 46
Lih-Jiun K 1254
Lim GK 148
Lim S-C 32
Lin C-C 1187, 1220
Lin C-K 337
Lin D-Y 682
Lin HH 682
Lin J-T 724, 1165, 1220
Lin K-C 682
Lin R 873
Lin SD 140
Lin Z-Y 190, 1192
Lindberg S1
Lindor K 196
Lindor KD S186
Liu W-W 1144
Llovet JM S428
Lo G-H 337
Lo SK 682
Lobo AJ 929, 1345
Locarnini SA 442, S322, S351, S471
Loffeld RJLF 542
Lu C-L 1254
Lu R 1144
Lu R-H 1254
Lu S-N 190, 1192, 1307
Luk J 1008
Luo J-C 1254
Luo Y-H 1144

McCaughan G 730
McCaughan GW 353
MacDonald GA 301
McDonald J 171
MacDonald RG 563
McHutchison JG 431
McLaughlin S 1329
Maccioni F 215
Machida S 897
Maddern G 889
Maeda S 556
Maeda T 535, 779
Maga T 27
Magami Y 262
Maher JJ 448
Maity AK 183
Majumdar D 183
Makino J 854
Malhotra V 165, 1312
Malkiewicz I 196
Malyutina SK 702
Manabe K 980
Manabe N 949
Manatsathit S S54
Mandal SK 183
Manns M S40
Manns MP S344, S389
Mansoor S S172
Marcon NE S85
Marguet D 66
Mariani G 1039
Marshall BJ 127
Masarrat S 1092
Masuda E 955
Masuda J-I 316, 1098
Masuda T 861
Masuzaki T 1064
Matsui M 897
Matsumoto A 1229
Matsumoto S 807
Matsumoto T 807
Matsuo I 316
Matsushima H 980
Matsuzaki Y 1133
Matsuzawa Y 659
Meagher AP 135
Meng JH S360
Menger MD 791
Mert A 72
Mesenas S S491
Mesenas SJ 148
Mikami N 216, 224, 1032, 1037
Mikami T 1078
Milkiewicz P 208
Min Y-D 32
Minami T 1040
Minato H 217
Mine T 651
Mirza D 208
Misra A 1331
Mitamura K 1198
Mitchell A 203
Mitra SK 6
Mitsuno Y 556, 1244
Miura S 606
Miwa T 651
Miyagawa J-I 659
Miyake K 1198
Miyaoka M 1070
Miyata T 332
Miyazaki J 1198
Miyazaki M 1049, 1056
Miyazaki Y 659
Miyoshi M 27, 748
Mizobuchi M 728
Mizokami M 671
Mizuguchi Y 779
Mizuno M 27, 748, 980
Mizuta K 1119
Mizuta Y 316, 1098
Moh MC S491
Mollison LC 127
Moradpour D S306, S413
Moreau R 739, 882, 1106
Morgan DJ 598
Mori H 807
Mori K 844
Mori N 1283
Morimoto T 535
Morinaga S 1110
Morita K 849
Moriya K 394
Moriyama N 779
Moriyasu F 262, 1070
Mukaihara S 535
Mulhall BP 1136
Munakata A 1278
Murakami H 1278
Muramatsu Y 779
Murase K 316, 1098
Murata H 955
Murata I 316, 1098
Murayama M 227

Nagahara Y 27
Naganuma M 105
Nagase H 1291
Nagree A 215
Nagy E 1170
Nagy G S50
Naik SR 1331
Nain CK 659
Naito I 980
Naito Y 728
Nakahara M 659
Nakaji S 1278
Nakajima A 1291
Nakajima K 91
Nakamura A 39, 1236
Nakamura K 535
Nakamura Y 535
Nakanishi T 772
Nakano M 772
Nakanuma Y 217, 1049, 1056, 1334
Nakashima H 1228
Nakashima M 1260
Nakashima O 994
Nakashima Y 994
Nakatsukasa H 285
Nakaya Y 1021

Nakayama T 1260
Nelson HS 167
Nemoto E 589
Neuman M 196
Ng FH 834
Ng HS 148, S491
Ng M 294, 908, 1001
Nguyen N 343
Ninomiya Y 980
Niwa Y 1283
Nobes MS 598
Noer HMS S508
Noguchi M 955
Noguchi Y 1110
Nomura M 1021
Norton ID 177
Nouso K 285

Obriadina A S360
Ochi F 1242
Ochi Y 1021
Ogawa M 849
Ogihara T 849
Oguma K 27, 748
Ogura K 556, 1244
Oguri A 1283
Ohashi A 332
Ohba K 316, 1098
Ohkusa T 849, 1078
Ohmiya N 1283
Ohmori O 1040
Ohta M 77
Ohtake Y 91
Ohtsuru A 1260
Ohyama T 844
Oikara H 861
Oka K 1070
Oka Y 980
Okabayashi Y 1242
Okabe T 227
Okada H 27, 748
Okada S 1205
Okamoto Y 1242
Okamura S 1021
Okayasu I 849, 1078
Okuda H 772
Okuda K 1, 91, 104, 216, 224, 230, 401, 806, 811, 1032, 1037, 1049, 1056, 1064, 1118, 1129, 1330, 1340, S204, S506
Okusaka T 1205
Olynyk JK 785
Omagari K 316, 1098
Omanwar S 1312
Omata M 556, 1244, S40, S434
Onda K 1070
O'Neill R 785
Ong JP 1136
Onishi T 697
Ooishi T 227
Oon CJ 148, S437, S491, S497, S500
Orito E 671
Ormonde DG 276
Oshiro K 1242
Ota Y 1198
Oyamatsu M 1236
Ozaras R 72
Ozbay G 72

Paik SW 914
Pan W 966
Panda SK S268
Pandey GK 1312
Pandit AN S403
Papanikolaou IS 1084
Paris MCJ 1170
Park JHY 563
Peng N-J 337
Pessione F 882
Peter S 1117
Pichoud C S460
Piratvisuth T S40
Pirola RC 177
Plaschke A 677
Plentz R S40
Poovorawan Y S155
Porov Y S300
Powell L 889
Powell LW 301, S191
Pramoolsinsup C S125
Puri P 6

Qiao L 973
Quintini G 1039

Ramakrishna BS 361, 1117, S54
Ramm GA 785
Ranjeev P 281
Rassiat E 882, 1106
Rela M S294
Reshetnikov OV 702
Rhee JC 914
Richter S 791
Rino Y 1110
Roberts-Thomson IC 103, 177, 343, 344, 621, 622, 721, 816, 923, 1031, 1117, 1227
Robins-Browne RM 467
Rodgers NG 1130
Rokuhara A 1229
Rosmawati M 281
Rudolph KL S40
Rutgeerts P S176
Ryabikov AN 702
Ryan P 177

Saal G 153
Sabra A S54
Saccone GTP 324
Sado Y 980
Saisho H 625
Saito A 772
Saito H 606
Saito K 1021
Saito T 1291, 1334
Saito Y 1153
Saitoh S 651
Saiton M 1040
Sakai Y S50
Sakamoto M 779
Saksena S S377
Sakurai Y 844
Salem H 110
Salerno F S242
Samarasinghe D 873
Samuel D S274, S408
Sander E 72
Sano K 535
Sano N 697
Sanyal AJ S248, S385
Sarin SK 165, 526, 765, 1312, S197, S214, S311, S482
Sasaki A 949
Sasaki K 1240
Sasaki T 1242
Sasaki Y 960
Sasayama Y 960
Satapathy SK S311
Sato A 140
Sato N 508, 849
Sato R 861
Sato T 955
Sato Y 844, 1198
Satoh Y 332
Sawa T 1098
Sawaoka H 960
Sayyah M 96
Schaffer BS 563
Schalm SW S338
Schliess F S256
Schmid R 636
Schmidt C 889
Schmidt G 110
Schuppan D S300
Segal E S50
Segal I 249
Seignères B S460
Sekihara H 1291
Sekine A 39, 1236
Sekine I 617, 1260
Selby W 233
Sen S 183
Senturk H 72
Seo JK 754
Seong J-S S424
Seto K 925
Sewell RB 598
Shackleton M 110
Shafik A 270, 1267
Shafik AA 1267
Shakhmatov 702
Shand AG 1161
Sharma BK 1312
Shear N 196
Sheu J-C 682
Shibatani N 708
Shih C-W 724
Shiina S S434

Shikama H 854
Shikuwa S 1260
Shimabukuro R 59, 77
Shimahara Y 1119
Shimatani M 708
Shimazu M 1211
Shin JW 52
Shinoda M 1211
Shinomura Y 659
Shirakawa K 140
Shirasaka T 1240
Shiratori Y 556, 1244, S434
Sievert W 295, 415
Sikuler E 1317
Simms KM 598
Sing G 889
Singh K 659
Singh V 659
Skiba G 208
Skinner P 723
Smallwood RA 598
Smout A S1
Soehendra N S50
Sogo T 617
Song B-C 52
Sourial M 1170
Speelman P S54
Spelbring J S365
Sripathi MS S370
Stableforth D 208
Steenvoorde P 805
Strassburg CP S389
Strong R 889
Su C-W 1187
Subbotin VM 589
Suematsu M 519
Sugano K 332
Sugano M 1242
Sugauchi F 671
Sugawara K 1278
Sugimachi K 59, 77
Sugimasa Y 1110
Suguhara S 81
Suh DJ 52, 345
Suh JI 839
Sun W-H 960
Sung JJY 369
Sung J-L 682, 1239
Sung K-B 52
Sung S-M 1239
Surangsrirat S S54
Suri S 6
Suzuki H 606, 1198
Suzuki K 140
Suzuki S 671
Suzuki T 994
Suzuki Y 1153
Svensson P-A 713
Sylla A S441
Szeto M-L 552

Tabak F 72
Tabassum S 577
Tagkalidis P 236
Tai D-I 682
Takagi A 651
Takakura R 659
Takamido S 708
Takanashi Y 1110
Takaoka M 708
Takasaki K 772
Takatsu K 772
Takayasu K 779
Take S 748
Takeda R 535
Takemiya S 1110
Takikawa H 697
Takikawa Y 140
Talley N 353, 825
Talley NJ 1247
Tam W 1227
Tam W 343
Tamada K 332
Tamgo T 1198
Tamiya Y 1236
Tamura K 1278
Tan C S491
Tan GS S491
Tan JY-L 908
Tan K S491
Tan YM 281
Tanabe M 1211
Tanaka A 535, 1119
Tanaka E 1229
Tanaka K 651, 1198, 1291
Tanaka M 758
Tanaka N 285
Tanaka S 949
Tanaka Y 1228
Tandon BN S504
Tandon R S15
Tandon RK 508, 816
Tang H-S 682
Tang VSY 1272
Tanimoto T 285
Tanoue K 59
Tateishi R S40
Tateiwa S 1242
Tatsuta M 955
Taylor AC 1161
Taylor RG 1170
Teague R S50
Telford J S15
Teng SW S491
Teo EK 908
Teo M 344, 1031, 1130
Terblanche J S439
Tesar P 889
Thakur V 165, 765
Theißen E 677
Thyagarajan SP S370
Toda G 308
Togawa J-I 1291
Tognarini D 153
Toh I S491
Tollenaar RAEM 805
Tomi T 1198
Tomikawa M 59, 77
Tomiyama T 332
Tomonari K-I 807
Toouli J 324, S15
Trauner M S105
Trehan MS 6
Trépo C S460
Trikha B 659
Trinta K S360
Tsai C-I 724
Tsai C-Y 1220
Tsai J-F 1192
Tso WK 1001
Tsou M-H 1239
Tsui TY 1008
Tsuji S 955, 960
Tsuji T 27, 285, 748, 980
Tsujii M 960
Tsuneyama K 217
Tung H-D 1307
Turner PC S441

Uchiyama K 728
Ueda R 671
Ueda Y 1119
Uehara K 81
Ueno H 1205
Ueno N 1291
Ulanova T S360
Umeda T 1198

Vaiphei K 659
Valla D 1106
Valla D-C 882, S224
Van Der Putten ABMM 542
Vanderwinden J-M 659
Vasistha RK 6
Verucchi G 1342
Vickers CR 135
Viiala C 127
Vogel A S389
Vollmar B 791
Vu CKF 1125

Wada S 332
Wakabayashi G 1211
Wakao F 779
Walsh MD 301
Walsh TS S172
Wang H-P 1165, 1220
Wang J-H 190, 1192, 1307
Wang L-Y 190, 1192
Wang M 66
Wang Q 1299
Wang TC 495
Wang WL 1008
Wang Y-Y 337
Watanabe H 1236
Watanabe K 217, 1070
Watanabe N 606
Watanabe O 227
Watanabe S 1240

Wedemeyer H S344, S389
Weigand J S344
Weinstein W S113
Weir RP 582
Weller P 208
Wettstein AR 135
Wiklaung I S72
Wild CP S441
Williams S 825
Wilson BC S85
Wilson I 987
Wilson JS 177
Wilson SR 800
Windsor HM 127
Wingate D S1
Wong BC-Y 629, 1323
Wong BCY 545, 834, 1001, 1272
Wong J 374
Wong SY 834, 1008
Wong W-M 924, 1001, 1323
Wong WM 834, 1272
Wong YH 545
Wu C-Y 1015
Wu J 973
Wu J-C 1187
Wu M-S 724, 1165, 1220

Xi H 1299
Xia HH-X 629
Xia HHX 1272
Xu C 973

Yaari A 1317
Yachha SK S228
Yagci RV 1087
Yagi K 39, 1236
Yamada M 1078
Yamagiwa S 81
Yamamoto M 772
Yamamoto S 708
Yamamoto T 1040
Yamamoto Y 1110, 1119
Yamaoka Y 535, 1119
Yamaura T 1229
Yang CH 839
Yang C-S 1165, 1220
Yang J-L 1144
Yang P-S 1239
Yang SH 52
Yang S-M 1144
Yang S-S 46, 682
Yang T-H 724, 1220
Yang ZF 1008
Yano H 994
Yano M 1021
Yee Y-K 552
Yeh H-Z 46
Yeomans N 488
Yeung K-W 190
Yokomizo H 227
Yokosuka O 625
Yokota K 27, 748
Yokoyama H 606
Yoneyama J 966

Yoon H-K 52
Yoshiba M 1198
Yoshida H 91, 556, 1244, S434
Yoshida N 728
Yoshida T 382, 1078
Yoshida Y 81
Yoshihara H 955
Yoshihara M 949
Yoshikawa T 728
Yoshimatsu K 227
Yoshimura N 1153
Yotsuya S 854
Young J 17, 301
Younossi ZM 1136
Yu E 345
Yu M-L 190, 1192
Yu Y 1299
Yuen H 1180
Yuen ST 834
Yueng Y-W 1180
Yukawa M 1240
Yumoto E 285
Yumoto Y 285
Yusoff IF 203, 276

Zeki S 606
Zeniya M 308
Zhao Y 148
Zhou Y 973
Zollner G S105
Zoulim F S460

Journal of Gastroenterology and Hepatology (2002) **17**, 1356–1380

Subject Index to Volume 17

Abstracts
Asian Pacific Association for the Study of the Liver Meeting 26–29 September 2002, Taipei A1–94 (September)
Asian Pacific Association for the Study of the Liver Commemorative International Congress on Viral Hepatitis, Prevention and Control A1061–1084 (December)
Australian Gastroenterology Week 2002 A95–196 (October)
Tenth Annual Conference of INASAL and EASL A1025–1060 (September)

[^{13}C]-urea breath test; protocol for Chinese 834
16S ribosomal RNA; granulomatous phlebitis (Case Report) 1334
4-hydroxynonenal; aldehydes do not directly activate hepatic stellate cells 785
8-hydroxy-deoxyguanosine; role of oxyradicals in chronic pancreatitis 606
'a' epitope; chronic hepatitis B virus carriers and 148
abdominal aorta; hepatic artery calcification 91
abdominal
discomfort, Chinese man with (Images of Interest) 1118, 1129
pain, recurrent; psychosocial factors and (Review) 1250
abdominoperineal resection; quality of life of rectal cancer patients 571
abscess, pyogenic liver; over 10 years 1001
absorption, intestinal; jejunal bile acid 697
accessories, endoscopic; infection control standards in endoscopy (Review) 361
acid
bile
cytokines in primary biliary cirrhosis 196
efficacy of colestimide in cholestasis (Editorial) 1133
jejunal absorption 697
ursodeoxycholic
cytokines in primary biliary cirrhosis 196
efficacy of colestimide in cholestasis (Editorial) 1133
jejunal bile acid absorption 697
active hepatitis, chronic; and hepatocellular carcinoma, cyclo-oxygenase-2 in 1110
acute
bleeding; drug therapy for portal hypertensive gastropathy 973
diarrhea; in adults (Working Party Report) S54
hepatic failure, etiopathogenesis of: Eastern versus Western countries (Review) S268
hepatitis
induced by traditional Chinese herbs used in the treatment of psoriasis (Letter to the Editor) 1342
A and acute hepatitis E 1187
urinary trypsin inhibitor in acute liver failure 140
liver failure; pediatric liver disease (Review) 521
pancreatitis; guidelines for management of (Working Party Report) S15
acyl glucuronide; hepatic covalent adduct formation 66
adaptation, intestinal; dietary complexity and interstitial 1170
adduct formation, covalent; hepatic 66
adenocarcinoma
esophageal cancer in the Asia–Pacific region (Review) 374
gastric; synchronous gastric tumors (Case Report) 1033
molecular pathology and gastric carcinoma 966
adenoma
colorectal villous (Images of Interest) 1031
evolution of colorectal cancer (Review) 17
of the ampulla of Vater (Images of Interest) 923
adenomatous
familial; south-east Scotland fundic gland polyps 1161
hyperplasia, atypical; hepatic nodules during computed tomography portography 779
polyposis, familial; genetic testing for colorectal cancer (Review) 389
adolescents; *Helicobacter pylori* infection in athletes 131
Advances in Gastrointestinal Endoscopy (Book Review) 230
adverse effects; management issues in hepatitis C (Review) 415
aflatoxin
and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: basis for primary prevention (Review) S441
natural history of hepatocellular carcinoma (Review) 401
agents, antiviral; advances in hepatitis C (Review) 442
alanine aminotransferase
in hepatitis C virus combination therapy 1307
levels; chronic hepatitis B virus carriers and 'a' epitope variants 148
albumin
dialysis-based extracorporeal liver assist device, molecular adsorbent recirculating system (Review) S280
prognostic factors of percutaneous ethanol injection 1205
alcoholic
chronic pancreatitis; metabolic genotypes in cirrhosis and pancreatitis 177
cirrhosis; metabolic genotypes in cirrhosis and pancreatitis 177
hepatitis; treatment of (Review) 448
alcoholic-metabolizing genotypes; in cirrhosis and pancreatitis 177
α chain; collagen in colon cancer 980
α-fetoprotein; lectin-reactive, and des-γ-carboxy prothrombin and hepatocellular carcinoma features, positivity of 772

α-interferon
lamivudine: clinical and economic outcomes 153
management of patients with chronic hepatitis B (Review) 406
ampulla of Vater, adenoma of the (Images of Interest) 923
amyloidosis
iron-deficiency anemia complicating AL (Case Report) 623
primary, gastrocolic fistula complicating (Letter to the Editor) 110
analogs, somatostatin; management of bleeding in cirrhotic patients (Review) 355
analysis, logistic; factors affecting endoscopic mucosal resection 845
anastomosis, ileoanal; predictors of surgical outcomes S167
anemia, iron-deficiency
complicating AL amyloidosis (Case Report) 623
predictors for colorectal cancer 281
angiogenesis
cholangiocarcinoma (Review) 1056
cyclo-oxygenase-2 and inducible nitric oxide synthase in pancreatic cancer 914
Helicobacter pylori and gastric ulcer 960
interleukin-6 and angiogenic factor 1165
angiography; recurrence of hepatocellular carcinoma following transcatheter arterial chemoembolization 52
animal model
of hepatitis B virus infection and anti-hepatitis B virus strategies (Review) S460
rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
anion-exchange resin; jejunal bile acid absorption 697
anoikis; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
antagonist
endothelin-3 and gallbladder contraction 324
histamine receptor
peptic ulcer disease (Review) 488
reversal of cirrhosis by TAK-044 589
antibody
antimitochondrial; enzyme inhibition assay in primary biliary cirrhosis 316
antineutrophil cytoplasmic; primary sclerosing cholangitis in Singapore 908
enzymatic mitochondrial; enzyme inhibition assay in primary biliary cirrhosis 316
monoclonal; new technologies for endoscopic diagnosis S85
serum; *Fusobacterium varium* in ulcerative colitis 849
to hepatitis E virus, new enzyme immunoassay for the detection of (Review) S360
antigen
Ki-67; β-catenin expression in hepatocellular carcinoma 994
proliferating cell nuclear; *Helicobacter pylori* promotes gastric carcinogenesis 253
s-; hepatitis B virus genotypes in India 165
antimitochondrial antibody; enzyme inhibition assay in primary biliary cirrhosis 316
antineutrophil cytoplasmic antibody; primary sclerosing cholangitis in Singapore 908
anti-oxidant therapy; treatment of alcoholic hepatitis (Review) 448
antisense gene; effect of on gastric carcinoma 1144
antituberculosis drugs in patients with chronic liver disease (Review) S408
antiviral
agents; advances in hepatitis C (Review) 442
drug; oxymatrine anti-hepatitis B virus mechanism 1299
therapy
hepatitis C advances in (Review) 431
non-response to, management issues in hepatitis C (Review) 415
treatment
of chronic hepatitis B (Review) 409
of patients with hepatitis B virus-related cirrhosis (Review) S306
antral intestinal metaplasia, and atrophic gastritis (Images of Interest) 1227
aorta, abdominal; hepatic artery calcification 91
apolipoprotein
A-1; scavenger receptor class B type 1 in gallbladder 713
B-100; scavenger receptor class B type 1 in gallbladder 713
E; metabolic genotypes in cirrhosis and pancreatitis 177
apoptosis
cyclo-oxygenase-2 and inducible nitric oxide synthase in pancreatic cancer 914
in ulcerative colitis 758
regulation of tumor necrosis factor- and interferon-γ-inducing 1283
roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced 651
approaches, psychological; management of irritable bowel syndrome (Review) 503
artery, splenic; hepatic calcification 91
ascites
pathogenesis of, and predictors of resistance to therapy (Review) S242
refractory, and hepatorenal syndrome (Review) 456
Asia–Pacific Digestive Week, First (Editorial) 353
aspartate aminotransferase elevation in a bed-ridden old man (Images of Interest) 806, 811
aspirin; peptic ulcer disease (Review) 488
assay, enzyme inhibiting; in primary biliary cirrhosis 316
assessment, nutritional; malnutrition and bone disease in cirrhosis patients (Review) 462
asyptomatic community; *Helicobacter pylori* in India 659
athletes; *Helicobacter pylori* infection in 131
atresia, biliary; pediatric liver disease (Review) 521
atrophic gastritis and antral intestinal metaplasia (Images of Interest) 1227
atrophy
gastric; cancer (Review) 495
glandular; *Helicobacter pylori* in reflux esophagitis 839
atypical adenomatous hyperplasia; hepatic nodules during computed tomography portography 779
autoimmune hepatitis and overlap syndromes (Review) S389
autonomic nervous activity; in endoscopic retrograde cholangiopancreatography 1021
autopsy; gallstone prevalence in Western Siberia 702

autoradiography, tritiated thymidine; cell renewal of stomach 262
azathioprine; and cyclosporin, development of ulcerative colitis despite long-term immunosuppression in an Australian Aborigine (Letter to the Editor) 1130

background, non-English-speaking; hepatitis C, general practitioners 295
bacterial
component; granulomatous phlebitis (Case Report) 1334
overgrowth, small bowel; gut-derived septicemia in strongyloidiasis (Case Report) 1331
resistance; management of *Helicobacter pylori* infection (Review) 482
band ligation, endoscopic; management of bleeding in cirrhotic patients (Review) 355
banding, esophageal; management of bleeding in cirrhotic patients (Review) 355
Barrett's esophagus
endoscopic mucosal resection (Review) 382
esophageal cancer in the Asia–Pacific region (Review) 374
role for high-resolution magnification chromoendoscopy (Review) 633
Barrett's mucosa; prevention and treatment of dysplasia in gastroesophageal reflux disease S113
basement membrane; collagen α (IV) chains in colon cancer 980
Behçet's disease; Behçet's colitis resembling Crohn's disease (Case Report) 105
benzbromarone; fulminant hepatic failure associated with treatment (Letter to the Editor) 625
β-blockers; non-alcoholic steatohepatitis (Review) 526
β-catenin; expression in hepatocellular carcinoma 994
Bifobacterium; prebiotic treatment of ulcerative colitis (Review) 818
bile
acid
cytokines in primary biliary cirrhosis 196
efficacy of colestimide in cholestasis (Editorial) 1133
jejunal absorption 697
duct
calculi, common; biliary intraductal ultrasonography 708
isolated; ethanol injection of isolated (Case Report) 807
ligation; opioids, nitric oxide and seizures 96
leak; ethanol injection of isolated duct (Case Report) 807
secretion; hepatic transport systems S105
biliary
atresia; pediatric liver disease (Review) 521
cirrhosis, primary
cytokines in 196
detection of nitrite and nitrate in 308
efficacy of colestimide in cholestasis (Editorial) 1133
enzyme inhibition assay in 316
drainage, endoscopic; use of guidewire 332
epithelium; cholangiocarcinoma (Review) 1056
pathology; pyogenic liver abscess over 10 years 1001
bilirubin; function of immortalized hepatocytes *in vivo* 690
biopsy
iron-deficiency anemia complicating AL amyloidosis (Case Report) 623
liver
hepatitis C in childhood (Review) 476
non-alcoholic fatty liver disease S186
mucosal; colonoscopy, ileoscopy for diarrhea 276
transpapillary; endothelin-3 and gallbladder contraction 324
bleeding
acute; drug therapy in portal hypertensive gastropathy 973
gastrointestinal; management of in cirrhotic patients (Review) 355
rectal; predictors for colorectal cancer 281
ulcer; *Helicobacter pylori* and gastric ulcer angiogenesis 960
variceal; rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
blood
donor; hepatitis C risk factors in Iranian donors 1092
gas; hypoxemia and cirrhosis 1106
body
cell mass; malnutrition and bone disease in cirrhosis patients (Review) 462
fat, percentage; non-alcoholic and non-obese fatty liver 1098
mass index
non-alcoholic and non-obese fatty liver 1098
steatosis in hepatitis C 873
bone disease, metabolic; and malnutrition in cirrhosis patients (Review) 462
bowel
diseases, 'developed society'; large bowel disease in Africans 249
small, bacterial overgrowth; gut-derived septicemia in strongyloidiasis (Case Report) 1331
symptoms; predictors for colorectal cancer 281
breast-feeding; hepatitis C in childhood (Review) 476
breath test
glucose hydrogen; gut-derived septicemia in strongyloidiasis (Case Report) 1331
hydrogen; delayed gastrointestinal transit in hepatocellular carcinoma patients 1254
bromodeoxyuridine; dysplasia–carcinoma in an ulcerative colitis model 1078
buried bumper syndrome; (Case Report) 1125
butyrate; prebiotic treatment of ulcerative colitis (Review) 818

Cajal, interstitial cells of; c-kit deficiency in diabetes mellitus 666
calcification; hepatic artery 91
calcium channels; endothelin-3 and gallbladder contraction 324
calculi, common bile duct; biliary intraductal ultrasonography 708
Cameron's erosions (Images of Interest) 343
cancer
colon; insulin-like growth factor-binding protein-6 and Caco-2 cell proliferation 563

colorectal
collagen α (IV) chains in 980
endoscopic mucosal resection (Review) 382
gastric; Fas and Fas ligand interaction 32
genetic testing for (Review) 389
hereditary non-polyposis (Review) 389
predictors for 281
early gastric
cardiac; after long-term gastroesophageal reflux disease (Case Report) 1236
factors affecting endoscopic mucosal resection 845
esophageal
endoscopic mucosal resection (Review) 382
tracheal involvement from (Images of Interest) 215
evolution of colorectal (Review) 17
gastric
endoscopic mucosal resection (Review) 382
Helicobacter pylori promotes 253
(Review) 495
hereditary non-polyposis colorectal
evolution of (Review) 17
pancreatic; cyclo-oxygenase-2 and inducible nitric oxide synthase in 914
predicting response in gastrointestinal cancer therapy S172
rectal; quality of life of 571
surgery, rectal; predictors of surgical outcomes S167
synchronous triple of esophagus and stomach (Case Report) 724
carbohydrate malabsorption; large bowel disease in Africans 249
carbon
monoxide; and abdominal surgery 535
tetrachloride; retinoids in hepatic fibrosis 791
carbonylhemoglobin; carbon monoxide and abdominal surgery 535
carcinogenesis; role of hepatitis C virus in development of hepatocellular carcinoma (Review) 394
carcinoid tumor, primary hepatic; with lymph node metastasis (Case Report) 1119
carcinoma
cholangio-hepatocellular; natural history of (Review) 401
colorectal; *int-2* in 1084
gastric
effect of antisense telomerase RNA on 1144
interleukin-6 and angiogenic factor 1165
hepatocellular
β-catenin expression in 994
comparison of from different countries (Working Party Report) S40
cyclo-oxygenase-2 in hepatitis 1110
delayed gastrointestinal transit 1254
dendritic cell-based immunotherapy for 889
dermatomyositis and erythrocytosis (Letter to the Editor) 1239
evidence-based medicine in the treatment of (Review) S428
hepatitis B viral genotypes 643
in India 165
in Thailand 671
hypermethylation and loss of heterozygosity at $p14^{ARF}$ 301
icteric type 190
in a responder to interferon therapy (Case Report) 1229
iron overloaded diseases S192
management of
hepatitis C virus S146
patients with chronic hepatitis B (Review) 406
mortality in families 682
natural
course and treatments, progression from chronic hepatitis to (Review) S434
history of (Review) 401
nodule-in-nodule; hepatic nodules during computed tomography portography 779
non-resectable, treatment of (Review) S424
OK-Lipo prolongs survival in rats 81
positivity of lectin-reactive α-fetoprotein, des-γ-carboxy prothrombin 772
prognostic factors of percutaneous ethanol injection 1205
recurrence of following transcatheter arterial chemoembolization 52
role of hepatitis C virus in development of (Review) 394
surgery for (Review) S421
treated with transcatheter arterial chemoembolization (Images of Interest) 104
viral pathogenesis of (Review) S413
squamous cell; esophageal, in the Asia–Pacific region (Review) 374
cardiac cancer, early gastric; after long-term gastroesophageal reflux disease (Case Report) 1236
care
post-therapy; endoscopic mucosal resection (Review) 382
primary; near patient test for *Helicobacter pylori* 1272
secondary; near patient test for *Helicobacter pylori* 1272
carvedilol; and propanolol in cirrhosis 183
case
–control; hepatitis C risk factors in Iranian donors 1092
of liver metastasis from colon cancer successfully treated by regional chemotherapy with mitomycin C alone (Letter to the Editor) 227
selection; treatment of chronic hepatitis B (Review) 409
CD26; hepatic covalent adduct formation 66
cell
body: mass; malnutrition and bone disease in cirrhosis patients (Review) 462
chief; renewal of stomach 262
colon cancer; insulin-like growth factor-binding protein-6 and Caco-2 proliferation 563
cycle; β-catenin expression in hepatocellular carcinoma 994
gastric
cancer; Fas and Fas ligand interaction 32
epithelial; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
hepatic stellate
3-D examination of 861
aldehydes do not directly activate 785
interferon-γ-producing; OK-Lipo prolongs survival of hepatocellular carcinoma in rats 81

interstitial; of Cajal; c-kit deficiency in diabetes mellitus 666
Kupffer; phagocytosis in malaria 598
migration; renewal of stomach 262
natural killer; OK-Lipo prolongs survival of hepatocellular carcinoma in rats 81
parietal; renewal of stomach 262
peripheral-blood mononuclear; glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
renewal of stomach 262
smooth muscle; renewal of stomach 262
stem: a dramatic new therapeutic tool (Review) 636
insulin-like growth factor-binding protein-6 and Caco-2 proliferation 563
cesarean section; hepatitis C in childhood (Review) 476
channels, calcium; endothelin-3 and gallbladder contraction 324
chemical disinfection; infection control standards in endoscopy (Review) 361
chief cells; renewal of stomach 262
childhood; combination therapy for chronic hepatitis B virus 1087
children
ferritin and *Helicobacter pylori* infection in 754
hepatitis C in (Review) 476
portal hypertension in: an Indian perspective (Review) S228
psychosocial factors and abdominal pain (Review) 1250
Chinese
Hong Kong index of dyspepsia 545
man with abdominal discomfort (Images of Interest) 1118, 1129
tea consumption and *Helicobacter* 552
Chlamydia pneumoniae; and inflammatory bowel disease 987
cholangiocarcinoma
(Review) 1049
with hepatolithiasis 1015
cholangio-hepatocellular carcinoma; natural history of (Review) 401
cholangitis, primary sclerosing; in Singapore 908
cholecystoenteric fistulae (Images of Interest) 344
choledochoduodenostomy
complications of (Images of Interest) 721
(Images of Interest) 622
choledocholithiasis; fatty meal and hepatic clearance 337
cholelithiasis, prevalence of in the general population at Chandigarh in northern India (Letter to the Editor) 1343
cholescintigraphy; fatty meal and hepatic clearance 337
cholestasis
extrahepatic manifestations of (Review) 938
intrahepatic; pediatric liver disease (Review) 521
hepatitis, fibrosing (Case Report) 345
liver disease
chronic (Review) S399
hepatic transport systems S105
cholesterol
scavenger receptor class B type 1 in gallbladder 713
steatosis in hepatitis C 873
chromogranin A; hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
chronic
active hepatitis; cyclo-oxygenase-2 in, and hepatocellular carcinoma 1110
cholestatic liver diseases (Review) S399
hepatitis
Stronger Neo-Minophagen C for 1198
to hepatocellular carcinoma, progression from: natural course and treatments (Review) S434
hepatitis B
combination
and newer therapies for (Review) S338
therapy for 1087
early antigen-negative (Review) S311
infection; management of patients with (Review) 406
interferon non-responsive
lamivudine: clinical and economic outcomes 153
management
of patients with (Review) 406
of YMDD mutations during lamivudine therapy in patients with (Review) S333
therapeutic vaccination in 72
treatment of (Review) 409
virus genotypes; 643
in India 165
in Thailand 671
hepatitis C
management issues in (Review) 415
mechanisms of drug resistance and novel approaches to therapy for (Review) S351
liver disease
antituberculosis drugs in patients with (Review) S408
hepatitis B
and C in, in New Zealand 582
virus genotypes in India 165
scoring severity of (Review) S298
pancreatitis
alcoholic; metabolic genotypes in cirrhosis and 177
consensus report (Review) 508
role of oxyradicals in 606
cirrhosis
alcoholic; and pancreatitis, metabolic genotypes in 177
carvedilol and propanolol in 183
delayed gastrointestinal transit in hepatocellular carcinoma patients 1254
hepatitis
B virus-related, antiviral treatment of patients with (Review) S306
C and risk of severe liver disease (Review) 423
hepatorenal syndrome in 739
hypoxemia and 1106
incomplete septal; non-cirrhotic portal fibrosis (Review) 6
liver
cyclo-oxygenase-2 in hepatitis and hepatocellular carcinoma 1110
effects of splenectomy on 77
hepatitis B viral genotypes 643
hepatogenous diabetes in 677
Stronger Neo-Minophagen C for chronic hepatitis 1198
malnutrition and bone disease in (Review) 462
management of
bleeding in (Review) 355

hepatitis C virus S146
patients with chronic hepatitis B (Review) 406
non-cirrhotic portal fibrosis (Review) 6
primary biliary
cytokines in 196
detection of nitrite and nitrate in 308
efficacy of colestimide in cholestasis (Editorial) 1133
enzyme inhibition assay in 316
refractory ascites and hepatorenal syndrome (Review) 456
retinoids in hepatic fibrosis 791
reversal of by TAK-044 589
terlipressin in type 1 hepatorenal syndrome 882
cis-acting elements; advances in hepatitis C (Review) 442
c-kit receptor tyrosine kinase; deficiency in diabetes mellitus 666
clarithromycin; management of *Helicobacter pylori* infection (Review) 482
classification; evolution of colorectal cancer (Review) 17
cleansing, manual; infection control standards in endoscopy (Review) 361
clearance, hepatic; fatty meal and 337
clinical
guidelines; infection control standards in endoscopy (Review) 361
outcome
hepatitis
B viral genotypes 643
C and risk of severe liver disease (Review) 423
C in childhood (Review) 476
relevance of viral dynamics and genotypes in hepatitis B virus (Review) S322
clinicopathologic features; positivity of lectin-reactive α-fetoprotein, des-γ-carboxy prothrombin and hepatocellular carcinoma features 772
clonic seizure threshold; opioids, nitric oxide and 96
Clostridium difficile colitis (Images of Interest) 103
cohorts, community-based; hepatitis C and risk of severe liver disease (Review) 423
colectomy, laparoscopic; predictors of surgical outcomes S167
colestimide
efficacy of in cholestasis (Editorial) 1133
jejunal bile acid absorption 697
colitis
Clostridium difficile (Images of Interest) 103
collagenous; microscopic 236
experimental; effect of IS-741 on 854
lymphocytic; microscopic 236
microscopic 236
ulcerative
apoptosis in 758
Chlamydia pneumoniae and inflammatory bowel disease 987
dysplasia–carcinoma in 1078
effect of IS-741 on experimental 854
Fusobacterium varium in 849
new therapies in inflammatory bowel disease S176
prebiotic treatment of (Review) 818
thalidomide in inflammatory bowel disease 135
collagen
aldehydes do not directly activate hepatic stellate cells 785
type IV; α chains in colon cancer 980
collagenous colitis; microscopic 236
collateral; pathology of fundic varices 1064
collecting venules, regular arrangement of; *Helicobacter pylori*-free stomach 39
colon
cancer
cell; insulin-like growth factor-binding protein-6 and Caco-2 proliferation 563
endoscopic mucosal resection (Review) 382
successfully treated by regional chemotherapy with mitomycin C alone, case of liver metastasis from (Letter to the Editor) 227
collagen α (IV) chains in cancer 980
evolution of colorectal cancer (Review) 17
colonic diverticulum, giant inflammatory (Images of Interest) 805
colonoscopy
colonoscopic teaching and training (Working Party Report) S50
conventional; in Chinese 1323
ileoscopy and mucosal biopsy for diarrhea 276
predictors for colorectal cancer 281
virtual; in Chinese 1323
colorectal
cancer
collagen α (IV) chains in 980
genetic testing for (Review) 389
hereditary non-polyposis
evolution of (Review) 17
genetic testing for (Review) 389
int-2 in 1084
laterally spreading tumors: clinical evaluation and endoscopic strategies updated (Letter to the Editor) 1344
predictors for 281
villous adenomas (Images of Interest) 1031
combination therapy
and newer therapies for chronic hepatitis B (Review) S338
hepatitis B virus; interferon non-responsive chronic hepatitis B 765
management issues in hepatitis C (Review) 415
treatment of chronic hepatitis B (Review) 409
common bile duct calculi; biliary intraductal ultrasonography 708
community, asymptomatic; *Helicobacter pylori* in India 659
community-based cohorts; hepatitis C and risk of severe liver disease (Review) 423
compensation, hepatic; management of patients with chronic hepatitis B (Review) 406
competitive polymerase chain reaction; glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
complications of choledochoduodenostomy (Images of Interest) 721
computed tomography
portography; hepatic nodules during 779
virtual colonoscopy in Chinese 1323
conditionally immortalized hepatocytes; function of *in vivo* 690
confocal laser scanning microscopy; 3-D examination of hepatic stellate cells 861

connective tissue disease; hepatitis C virus infection and autoimmunity (Editorial) 814
consensus
management of patients with chronic hepatitis B (Review) 406
recommendations; chronic pancreatitis consensus report (Review) 508
summaries from Asian Pacific Association for the Study of the Liver Commemorative International Congress on Viral Hepatitis, Prevention and Control S511
consistency, fecal; in the Japanese population 1278
control, infection; standards in endoscopy (Review) 361
conventional colonoscopy; in Chinese 1323
copper
hepatic transport systems S105
metabolic defects and liver disease: environmental aspects (Review) S403
core protein; role of hepatitis C virus in development of hepatocellular carcinoma (Review) 394
corpus, magnified views of normal; *Helicobacter pylori*-free stomach 39
corticosteroid
priming; management of patients with chronic hepatitis B (Review) 406
treatment of alcoholic hepatitis (Review) 448
cost-effectiveness
lamivudine: clinical and economic outcomes 153
management of bleeding in cirrhotic patients (Review) 355
covalent adduct formation; hepatic 66
covalently closed circular DNA; management of patients with chronic hepatitis B (Review) 406
criteria
diagnostic; management of irritable bowel syndrome (Review) 503
Rome II; prevalence of irritable bowel disease 1180
Crohn's disease
Behçet's colitis resembling (Case Report) 105
bowel disease and inflammatory molecules (Editorial) 935
Chlamydia pneumoniae and inflammatory bowel disease 987
glucocorticoid receptor messenger RNA in lymphocytes 1070
new therapies in inflammatory bowel disease S176
thalidomide in inflammatory bowel disease 135
curative treatment; endoscopic mucosal resection (Review) 382
cyclo-oxygenase-2
and inducible nitric oxide synthase in pancreatic cancer 914
in hepatitis and hepatocellular carcinoma 1110
inhibitors; peptic ulcer disease (Review) 488
cyclosporin; and azathioprine, development of ulcerative colitis despite long-term immunosuppression in an Australian Aborigine (Letter to the Editor) 1130
cynomolgus macaques, DNA vaccination against hepatitis E virus infection in (Review) S365
cystic fibrosis
hepatic transport systems S105
liver transplantation in 208
cytokine
in primary biliary cirrhosis 196
T helper cell 1 and 2; oxymatrine anti-hepatitis B virus mechanism 1299
cytomegalovirus; phenytoin and cytomegalovirus ileitis (Letter to the Editor) 1240
cytotoxic T-lymphocytes; antigen presentation in hepatoma 897

damage, vascular; overlap of idiopathic portal hypertension and scleroderma (Case Report) 217
decision analysis; lamivudine: clinical and economic outcomes 153
deficiency, iron; ferritin and *Helicobacter pylori* infection in children 754
dendritic cell-based immunotherapy for hepatocellular carcinoma 889
dermatomyositis; and erythrocytosis (Letter to the Editor) 1239
des-γ-carboxy prothrombin; positivity of lectin-reactive α-fetoprotein, and hepatocellular carcinoma features 772
developed society large bowel disease; in Africans 249
development of ulcerative colitis despite long-term immunosuppression with cyclosporin and azathioprine in an Australian Aborigine (Letter to the Editor) 1130
dextran sulfate sodium
dysplasia–carcinoma in an ulcerative colitis model 1078
lactoferrin reduces colitis in rats 1291
diabetes
hepatogenous; in liver cirrhosis 677
mellitus
c-kit deficiency in 666
pyogenic liver abscess over 10 years 1001
diagnosis
changing role of endoscopy (Review) 369
chronic pancreatitis consensus report (Review) 508
of hepatitis C virus; in childhood (Review) 476
recurrence of hepatocellular carcinoma following transcatheter arterial chemoembolization 52
refractory ascites and hepatorenal syndrome (Review) 456
diagnostic
criteria; management of irritable bowel syndrome (Review) 503
technology; gut dysmotility: a new classification (Working Party Report) S1
diamniotic monozygous twins, monochorionic; different hepatitis C virus transmission in 617
diarrhea
acute; in adults (Working Party Report) S54
colonoscopy, ileoscopy and mucosal biopsy for 276
Escherichia coli and (Review) 467
microscopic colitis 236
dietary
complexity; and interstitial adaptation 1170
factors; gastric cancer (Review) 495
fiber
fecal consistency in the Japanese population 1278
low intake; large bowel disease in Africans 249
prebiotic treatment of ulcerative colitis (Review) 818
dipeptidyl peptidase IV; hepatic covalent adduct formation 66
disease
activity; fatigue and hepatitis C 171

progression; hepatitis C and risk of severe liver disease (Review) 423
recurrence, liver transplants and (Editorial) 733
disinfection, chemical; infection control standards in endoscopy (Review) 361
disorders, motor; gut dysmotility: a new classification (Working Party Report) S1
disoriented woman (Images of Interest) 216, 224
diverticulum, colonic; giant inflammatory (Images of Interest) 805
DNA
covalently closed circular; management of patients with chronic hepatitis B (Review) 406
vaccination against hepatitis E virus infection in cynomolgus macaques (Review) S365
donor, blood; hepatitis C risk factors in Iranian 1092
drainage, endoscopic biliary; use of biliary guidewire 332
drug resistance, mechanisms of, and novel approaches to therapy for chronic hepatitis C (Review) S351
drug-resistant strain; hepatitis B surface gene variation (Editorial) 933
duct, bile
isolated; ethanol injection of (Case Report) 807
ligation; opioids, nitric oxide and seizures 96
duodenal
diverticulum bleeding; treatment of (Letter to the Editor) 1242
ulcer
mucosal IgA deposition in Henoch–Schönlein purpura with (Letter to the Editor) 728
roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
duodenum; iron-deficiency anemia complicating AL amyloidosis (Case Report) 623
dyspepsia; Hong Kong index of 545
dysphagia; gastro-oesophageal reflux disease: guidelines for clinicians (Special Report) 825
dysplasia
cholangiocarcinoma (Review) 1056
mouse model; –carcinoma in an ulcerative colitis model 1078
new technologies for endoscopic diagnosis S85
prevention and treatment in gastroesophageal reflux disease S113
dysrhythmia, gastric; slow-wave 46

early gastric cancer; factors affecting endoscopic mucosal resection 845
effects, adverse; management issues in hepatitis C (Review) 415
electrical waves in small intestine; ileo–ileal inhibitory reflex 1267
electrogastrography; gastric slow-wave dysrhythmia 46
elements, *cis*-acting; advances in hepatitis C (Review) 442
encephalopathy, hepatic
pathogenesis (Review) S256
management of (Review) S260
endoscope reprocessors; infection control standards in endoscopy (Review) 361
endoscopic
accessories; infection control standards in endoscopy (Review) 361
band ligation; management of bleeding in cirrhotic patients (Review) 355
biliary drainage; use of guidewire 332
finding of normal stomach; *Helicobacter pylori*-free 39
gastrostomy, percutaneous; buried bumper syndrome (Case Report) 1125
injection therapy; treatment of duodenal diverticulum bleeding (Letter to the Editor) 1242
mucosal resection
factors affecting 845
(Review) 382
retrograde cholangiopancreatography
biliary intraductal ultrasonography 708
endothelin-3 and gallbladder contraction 324
in autonomic nervous activity 1021
sclerotherapy
management of bleeding in cirrhotic patients (Review) 355
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic portal fibrosis (Review) 6
screening; genetic testing for colorectal cancer (Review) 389
sphincterotomy; fatty meal and hepatic clearance 337
strategies, colorectal laterally spreading tumors: clinical evaluation (Letter to the Editor) 1344
therapy
chronic pancreatitis consensus report (Review) 508
esophageal cancer in the Asia–Pacific region (Review) 374
variceal ligation; non-alcoholic steatohepatitis (Review) 526
endoscopy
changing role of (Review) 369
colonoscopic teaching and training (Working Party Report) S50
gastrointestinal; infection control standards in (Review) 361
Helicobacter pylori in India 659
endosonography; biliary intraductal ultrasonography 708
endothelial growth factor, vascular; interleukin-6 and angiogenic factor 1165
endothelin
-1, 3-D examination of hepatic stellate cells 861
-3; and gallbladder contraction 324
antagonists; and gallbladder contraction 324
hypoxemia and cirrhosis 1106
reversal of cirrhosis by TAK-044 589
end-stage liver disease; malnutrition and bone disease in cirrhosis patients (Review) 462
enolase, neuron-specific; hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
enteric nervous system; management of irritable bowel syndrome (Review) 503
enteropathogens; acute diarrhea in adults (Working Party Report) S54
enzymatic mitochondrial antibody; enzyme inhibition assay in primary biliary cirrhosis 316
enzyme
immunoassay for the detection of antibody to hepatitis E virus, new (Review) S360
inhibiting assay; in primary biliary cirrhosis 316
epidemiology
acute hepatitis A and acute hepatitis E 1187

and prophylaxis of viral hepatitis S155
esophageal cancer in the Asia–Pacific region (Review) 374
gastric cancer (Review) 495
Helicobacter pylori in India 659
hepatitis B and C in chronic liver disease in New Zealand 582
management of hepatitis C virus S146
molecular; hepatitis B viral genotypes 643
newly developing hiatus hernia 542
prevalence of irritable bowel disease 1180
primary sclerosing cholangitis in Singapore 908
epinephrine injection; endoscopic for a bleeding marginal ulcer 1220
epithelial cells, gastric; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
epithelioid granuloma; Behçet's colitis resembling Crohn's disease (Case Report) 105
epithelium, biliary; cholangiocarcinoma (Review) 1056
epitope, 'a' variants; chronic hepatitis B virus carriers and 148
eradication
management of *Helicobacter pylori* infection (Review) 482
therapy; reinfection rate of *Helicobacter pylori* 27
erosions, Cameron's (Images of Interest) 343
erthyrocytosis; and dermatomyositis (Letter to the Editor) 1239
Escherichia coli
and diarrhea (Review) 467
gut-derived septicemia in strongyloidiasis (Case Report) 1331
esophageal
banding; management of bleeding in cirrhotic patients (Review) 355
cancer
endoscopic mucosal resection (Review) 382
tracheal involvement from (Images of Interest) 215
motility; low-grade reflux esophagitis 949
neoplasm; cancer in the Asia–Pacific region (Review) 374
varices; management of bleeding in cirrhotic patients (Review) 355
esophagitis, reflux
and proton pump inhibitor 955
Helicobacter pylori in 839
low-grade 949
natural history of (Editorial) 1247
esophagus
Barrett's
cancer in the Asia–Pacific region (Review) 374
endoscopic mucosal resection (Review) 382
predicting response in gastrointestinal cancer therapy S172
ethanol injection
percutaneous; prognostic factors of 1205
therapy; of isolated bile duct (Case Report) 807
ethnicity; hepatitis B and C in chronic liver disease in New Zealand 582
etiology
Chlamydia pneumoniae and inflammatory bowel disease 987
comparison of hepatocellular carcinoma from different countries (Working Party Report) S40
etiopathogenesis
acute hepatic failure: Eastern versus Western countries (Review) S268
hepatocellular carcinoma, role of aflatoxins and hepatitis viruses in: basis for primary prevention (Review) S441
Eubacterium limosum; prebiotic treatment of ulcerative colitis (Review) 818
EuroQol; quality of life of rectal cancer patients 571
evidence-based
guidelines; chronic pancreatitis consensus report (Review) 508
medicine in the treatment of hepatocellular carcinoma (Review) S428
exacerbation; apoptosis in ulcerative colitis 758
experimental
colitis; effect of IS-741 on 854
study; shepherds of science (Editorial) 816
external removal; buried bumper syndrome (Case Report) 1125
extrahepatic portal vein obstruction
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic portal fibrosis (Review) 6

factors, dietary; gastric cancer (Review) 495
failure, renal
hepatic artery calcification 91
hepatorenal syndrome in cirrhosis 739
familial
adenomatous
polyposis
genetic testing for colorectal cancer (Review) 389
high-magnification-chromoscopic-colonoscopy (Letter to the Editor) 929
south-east Scotland fundic gland polyps 1161
tendency; mortality in hepatocellular carcinoma 682
famotidine; reflux esophagitis and proton pump inhibitor 955
Fas
and Fas ligand interaction 32
and tumor necrosis factor-α-receptor type 1, role in *Helicobacter pylori*-induced apoptosis 651
fat, body percentage; non-alcoholic and non-obese fatty liver 1098
fatigue
and hepatitis C 171
extrahepatic manifestations of cholestasis (Review) 938
fatty
liver
disease, non-alcoholic
and non-obese 1098
(Review) 1136
treatment of (Review) S385
steatosis in hepatitis C 873
meal; and hepatic clearance 337
fecal
consistency; in the Japanese population 1278
water; in the Japanese population 1278
weight; in the Japanese population 1278
ferritin; and *Helicobacter pylori* infection in children 754
ferroprotein; hepatocellular carcinoma and iron overloaded diseases S192

fiber, dietary
complexity and interstitial adaptation 1170
fecal consistency in the Japanese population 1278
low intake; large bowel disease in Africans 249
prebiotic treatment of ulcerative colitis (Review) 818
fibrogenesis; aldehydes do not directly activate hepatic stellate cells 785
fibromellar variant, natural history of hepatocellular carcinoma (Review) 401
fibrosing cholestatic hepatitis (Case Report) 345
fibrosis
cytokines in primary biliary cirrhosis 196
hepatic
from bench to bedside (Review) S300
retinoids in 791
liver, role of the spleen in 59
non-cirrhotic portal
(Review) 6, S214
non-alcoholic steatohepatitis (Review) 526
rabbit model of by immunosensitization 1312
overlap of idiopathic portal hypertension and scleroderma (Case Report) 217
reversal of cirrhosis by TAK-044 589
steatosis in hepatitis C 873
First Asia–Pacific Digestive Week (Editorial) 353
fistula
cholecystoenteric (Images of Interest) 344
ethanol injection of isolated bile duct (Case Report) 807
gastrocolic, complicating primary amyloidosis (Letter to the Editor) 110
flares, hepatitis, management of patients with chronic hepatitis B (Review) 406
flat adenoma syndrome; high-magnification-chromoscopic-colonoscopy (Letter to the Editor) 929
fluorescence
microscopy; retinoids in hepatic fibrosis 791
new technologies for endoscopic diagnosis S85
formation, stroma; cholangiocarcinoma (Review) 1056
fulminant
hepatic failure; serum interleukin-18 and interleukin-10 levels in 285
hepatitis; urinary trypsin inhibitor in acute liver failure 140
fundic
gland polyp; south-east Scotland 1161
varices; pathology of 1064
Fusobacterium varium; in ulcerative colitis 849

gallbladder
motility; endothelin-3 and contraction 324
porcelain (Images of Interest) 1228
scavenger receptor class B type 1 in 713
gallstones
guidelines for management of acute pancreatitis (Working Party Report) S15
prevalence in Western Siberia 702
γ-interferon
antigen presentation in hepatoma 897
Fas and Fas ligand interaction 32
Gardner syndrome; genetic testing for colorectal cancer (Review) 389
gas, blood; hypoxemia and cirrhosis 1106

gastric
adenocarcinoma; synchronous tumors (Case Report) 1033
atrophy; cancer (Review) 495
biopsy-based rapid urease tests for the detection of *Helicobacter pylori* (Editorial) 629
cancer
cardiac, early; after long-term gastroesophageal reflux disease (Case Report) 1236
cells; Fas and Fas ligand interaction 32
early, factors affecting endoscopic mucosal resection 845
endoscopic mucosal resection (Review) 382
Helicobacter pylori promotes gastric carcinogenesis 253
(Review) 495
carcinoma
effect of antisense telomerase RNA on 1144
interleukin-6 and angiogenic factor 1165
dysrhythmia; slow-wave 46
epithelial cells; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
motility; parathyroid hormone-related peptide and 1260
ulcer; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
varices; management of bleeding in cirrhotic patients (Review) 355
gastrin; gastric cancer (Review) 495
gastrocolic fistula complicating primary amyloidosis (Letter to the Editor) 110
gastroenteritis
acute diarrhea in adults (Working Party Report) S54
Escherichia coli and diarrhea (Review) 467
gastroenterology; health-related quality of life and gastrointestinal disease S72
gastroesophageal reflux disease
cancer after long-term (Case Report) 1236
guidelines for clinicians (Special Report) 825
newly developing hiatus hernia 542
prevention and treatment of dysplasia in S113
gastrointestinal
bleeding; management of in cirrhotic patients (Review) 355
endoscopy; infection control standards in (Review) 361
motility; gut dysmotility: a new classification (Working Party Report) S1
transit; delayed in hepatocellular carcinoma patients 1254
gastropathy, portal hypertensive
drug therapy for acute bleeding in 973
non-alcoholic steatohepatitis (Review) 526
gastroscopy; iron-deficiency anemia complicating AL amyloidosis (Case Report) 623
gastrostomy, percutaneous endoscopic; buried bumper syndrome (Case Report) 1125
GB virus C; TT virus in a hepatitis C virus/hepatitis B virus endemic township 1192
gene
antisense; effect of antisense telomerase RNA on gastric carcinoma 1144
hepatitis B virus S; oxymatrine anti-hepatitis B virus mechanism 1299

mutations; genetic testing for colorectal cancer (Review) 389
therapy
effect of antisense telomerase RNA on gastric carcinoma 1144
retroviral gene transfer to the rat liver graft 1008
tumor suppressor; molecular pathology and gastric carcinoma 966
general practice; hepatitis C 295
genetic
instability; evolution of colorectal cancer (Review) 17
testing; for colorectal cancer (Review) 389
variation; hepatitis B surface (Editorial) 933
genomic variability; hepatitis B viral genotypes 643
genotype
alcoholic-metabolizing; cirrhosis and pancreatitis 177
hepatitis B
clinical relevance of viral dynamics (Review) S322
viral 113, 643
virus
in India 165
interferon non-responsive chronic 765
steatosis in hepatitis C 873
genotyping; hepatitis B virus in Thailand 671
geographic variation; natural history of hepatocellular carcinoma (Review) 401
geranylgeranlyacetone; effect of, on interleukin-8 production 1153
giant inflammatory colonic diverticulum (Images of Interest) 805
gland, peribiliary; cholangiocarcinoma (Review) 1056
glandular atrophy; *Helicobacter pylori* in reflux esophagitis 839
glial fibrillary acidic protein; 3-D examination of hepatic stellate cells 861
glucocorticoid receptor messenger RNA; in Crohn's disease lymphocytes 1070
glucose hydrogen breath test; gut-derived septicemia in strongyloidiasis (Case Report) 1331
glutamic oxaloacetic transaminase; prognostic factors of percutaneous ethanol injection 1205
glutathione
role of oxyradicals in chronic pancreatitis 606
S-transferases; metabolic genotypes in cirrhosis and pancreatitis 177
glycyrrhizin; Stronger Neo-Minophagen C for chronic hepatitis 1198
graft rejection; new approaches for immunosuppression (Review) 116
granulocyte-macrophage colony-stimulating factor; interferon non-responsive chronic hepatitis B 765
granuloma, epithelioid; Behçet's colitis resembling Crohn's disease (Case Report) 105
granulomatous phlebitis of the liver (Case Report) 1334
Grimelius stain; hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
guidelines
clinical; infection control standards in endoscopy (Review) 361
evidence-based; chronic pancreatitis consensus report (Review) 508
guidewire; endothelin-3 and gallbladder contraction 324
Gunn rats; function of immortalized hepatocytes *in vivo* 690
gut motility; ileo–ileal inhibitory reflex 1267

Haemaccel; volume restitution in portal hypertension 1317
heart rate variability; autonomic nervous activity in endoscopic retrograde cholangiopancreatography 1021
heater probe; endoscopic for a bleeding marginal ulcer 1220
helicase; advances in hepatitis C (Review) 442
Helicobacter pylori
[^{13}C]-urea breath test protocol for Chinese 834
cancer after long-term gastroesophageal reflux disease (Case Report) 1236
effect of geranylgeranlyacetone on interleukin-8 production 1153
gastric biopsy-based rapid urease tests for the detection of (Editorial) 629
gastric cancer (Review) 495
in India 659
in reflux esophagitis 839
-induced apoptosis, roles of tumor necrosis factor-α-receptor type 1 and Fas in 651
infection
in athletes 131
in children, and ferritin 754
management of (Review) 482
low-grade reflux esophagitis 949
near patient test for 1272
-negative normal stomach; -free stomach 39
new formulation CLOtest 127
nuclear factor-κB activation of 556, 1244
promotes gastric carcinogenesis 253
proton pump inhibitor in triple therapy with *CYP2C19* 748
regulation of tumor necrosis factor- and interferon-γ-inducing apoptosis 1283
reinfection rate of 27
south-east Scotland fundic gland polyps 1161
tea consumption and 552
hematemesis; gastro-oesophageal reflux disease: guidelines for clinicians (Special Report) 825
heme oxygenase; carbon monoxide hemoglobin, a stress-induced marker (Editorial) 519
hemochromatosis
hepatocellular carcinoma and iron overloaded diseases S192
testing for 800
hemoclip; endoscopic for a bleeding marginal ulcer 1220
hemodialysis; hepatic artery calcification 91
hemodynamics; carvedilol and propanolol in cirrhosis 183
hemolytic uremic syndrome; and whole splenic infarction (Letter to the Editor) 1040
hemorrhage, variceal; non-alcoholic steatohepatitis (Review) 526
Henoch–Schönlein purpura with duodenal ulcer, mucosal IgA deposition in (Letter to the Editor) 728
hepatectomy; carbon monoxide and abdominal surgery 535
hepatic
artery; calcification 91
carcinoid tumor, primary; with lymph node metastasis (Case Report) 1119

clearance; fatty meal and 337
compensation; management of patients with chronic hepatitis B (Review) 406
copper transport; systems S105
encephalopathy
pathogenesis of (Review) S256
management of (Review) S260
failure
acute, etiopathogenesis of: Eastern versus Western countries (Review) S268
fulminant; serum interleukin-18 and interleukin-10 levels in 285
treatment of patients with (Review) S274
fibrosis
from bench to bedside (Review) S300
microcirculation; retinoids in 791
nodule; during computed tomography portography 779
regeneration; role of the spleen in liver fibrosis 59
stellate cell
3-D examination of 861
aldehydes do not directly activate 785
and oxidative stress (Editorial) 1045
veins; granulomatous phlebitis (Case Report) 1334
hepatitis
A; acute, and acute hepatitis E 1187
acute
A and E 1187
induced by traditional Chinese herbs used in the treatment of psoriasis (Letter to the Editor) 1342
urinary trypsin inhibitor in acute liver failure 140
alcoholic; treatment of (Review) 448
and liver disease
in Hong Kong (Review) S510
in Indonesia (Review) S508
autoimmune, and overlap syndromes (Review) S389
B
and C
in chronic liver disease in New Zealand 582
summary and recommendations of single theme conferences on S197
early antigen-negative chronic (Review) S311
immunologic intervention in the pathogenesis, prophylaxis and therapeusis of (Review) S449
mortality in hepatocellular carcinoma families 682
surface antigen mutants in Singapore patients; molecular characterization of (Review) S491
weighing the costs of treatment (Editorial) 737
B virus
animal model of and anti-hepatitis B virus strategies (Review) S460
chronic
combination and newer therapies for (Review) S338
combination therapy for 1087
early antigen-negative (Review) S311
flares; management of patients with (Review) 406
genotypes in Thailand 671
interferon non-responsive 765
lamivudine: clinical and economic outcomes 153
management of YMDD mutations during lamivudine therapy in patients with (Review) S333
mutants (Review) S497
therapeutic vaccination in 72
treatment of (Review) 409
virus carriers and 'a' epitope variants 148
clinical relevance of viral dynamics and genotypes in (Review) S322
combination therapy; interferon non-responsive chronic 765
comparison of hepatocellular carcinoma from different countries (Working Party Report) S40
discovery of and invention of vaccine (Review) S502
fibrosing cholestatic (Case Report) 345
genotype 643
(Editorial) 113
in India 165
interferon non-responsive chronic 765
infection
chronic; management of patients with (Review) 406
immunogenetics of (Review) S329
interferon non-responsive chronic 765
management of S125
prevalence in non-Hodgkin's lymphoma (Letter to the Editor) 1039
-related cirrhosis, antiviral treatment of patients with (Review) S306
S gene; oxymatrine anti-hepatitis B virus mechanism 1299
Stronger Neo-Minophagen C for chronic 1198
subtypes; genotypes in India 165
surface gene variation (Editorial) 933
TT virus in a hepatitis C virus/hepatitis B virus endemic township 1192
C
advances in antiviral therapy (Review) 431
alanine aminotransferase in combination therapy 1307
and B
emerging therapies of (Review) S471
in chronic liver disease in New Zealand 582
summary and recommendations of single theme conferences on S197
chronic
autoantibody with (Case Report) 927
interferon with ribavirin for 577
management issues in (Review) 415
mechanisms of drug resistance and novel approaches to therapy for (Review) S351
fatigue and 171
general practitioners 295
mortality in hepatocellular carcinoma families 682
risk
factors in Iranian donors 1092
of severe liver disease (Review) 423
steatosis in 873
C virus
advances in (Review) 442
alanine aminotransferase in combination therapy 1307
cholangiocarcinoma (Review) 1049
clades and properties (Review) S468
comparison of hepatocellular carcinoma from different countries (Working Party Report) S40
diagnosis of; in childhood (Review) 476
hepatitis B virus endemic township, TT virus in 1192

hepatitis prevalence in non-Hodgkin's lymphoma (Letter to the Editor) 1039
hepatocellular carcinoma in a responder to interferon therapy (Case Report) 1229
infection
and autoimmunity (Editorial) 814
in childhood (Review) 476
role in development of hepatocellular carcinoma (Review) 394
Stronger Neo-Minophagen C for 1198
therapy, polyethylene glycol–interferon: current status in (Review) S344
chronic
active; hepatocellular carcinoma and cyclo-oxygenase-2 in 1110
progression to hepatocellular carcinoma: natural course and treatments (Review) S434
Stronger Neo-Minophagen C for 1198
E virus
acute hepatitis A and 1187
infection in cynomolgus macaques, DNA vaccination against (Review) S365
new enzyme immunoassay for the detection of antibody to (Review) S360
fibrosing cholestatic (Case Report) 345
fulminant; urinary trypsin inhibitor in acute liver failure 140
G virus; TT virus in a hepatitis C virus/hepatitis B virus endemic township 1192
studies in Japan (Review) S506
viral
pediatric liver disease (Review) 521
public health measures in the control of (Review) S452
virus
and aflatoxins in the etiopathogenesis of hepatocellular carcinoma: basis for primary prevention (Review) S441
epidemiology and prophylaxis of S155
natural history of hepatocellular carcinoma (Review) 401
(Review) S464
virus–hepatocyte interactions, molecular mechanisms of (Review) S342
Hepatobiliary Diseases: Pathophysiology and Imaging (Book Review) 730
hepatocellular carcinoma
and cyclo-oxygenase-2 in hepatitis 1110
and iron overloaded diseases S192
β-catenin expression in 994
comparison of from different countries (Working Party Report) S40
delayed gastrointestinal transit in 1254
dendritic cell-based immunotherapy for 889
dermatomyositis and erythrocytosis (Letter to the Editor) 1239
evidence-based medicine in the treatment of (Review) S428
hepatitis B
viral genotypes 643
virus genotypes
in India 165
in Thailand 671
hypermethylation and loss of heterozygosity at *p14*^{ARF} in 301
icteric type 190
in a responder to interferon therapy (Case Report) 1229
management of
hepatitis C virus S146
patients with chronic hepatitis B (Review) 406
mortality in 682
natural
course and treatments, progression from chronic hepatitis to (Review) S434
history of (Review) 401
nodule-in-nodule; hepatic nodules during computed tomography portography 779
non-resectable, treatment of (Review) S424
OK-Lipo prolongs survival in rats 81
positivity of lectin-reactive α-fetoprotein, des-γ-carboxy prothrombin 772
prevention of lymphoblastoid α interferon (Review) S500
prognostic factors of percutaneous ethanol injection 1205
recurrence of following transcatheter arterial chemoembolization 52
role of aflatoxins and hepatitis viruses in the etiopathogenesis of: basis for primary prevention (Review) S441
role of hepatitis C virus in development of (Review) 394
surgery for (Review) S421
treated with transcatheter arterial chemoembolization (Images of Interest) 104
viral pathogenesis of (Review) S413
hepatocyte
fulminant hepatic failure associated with benzbromarone treatment (Letter to the Editor) 625
transplantation
immortalized; function of *in vivo* 690
(Review) S287
hepatocytotoxicity; cytokines in primary biliary cirrhosis 196
hepatogenous diabetes; in liver cirrhosis 677
hepatolithiasis
cholangiocarcinoma (Review) 1049
with cholangiocarcinoma 1015
hepatoma
antigen presentation in 897
gastric slow-wave dysrhythmia 46
hepatoportal sclerosis; non-cirrhotic portal fibrosis (Review) 6
hepatopulmonary syndrome, portopulmonary hypertension and (Review) S253
hepatorenal syndrome
refractory ascites and (Review) 456
(Review) S248
terlipressin in type 1 882
herbal medicine for liver disease in India (Review) S370
hereditary non-polyposis colorectal cancer
evolution of (Review) 17
genetic testing for (Review) 389
hernia, hiatus; newly developing 542
heterozygosity, loss of; hypermethylation and, at *p14*^{ARF} in hepatocellular carcinoma 301
hiatus hernia, newly developing 542

high-density lipoprotein; scavenger receptor class B type 1 in gallbladder 713
high-resolution magnification chromoendoscopy, Barret's esophagus: a role for (Review) 633
hindrance, vascular; volume restitution in portal hypertension 1317
histamine receptor antagonists; peptic ulcer disease (Review) 488
histiocyte; apoptosis in ulcerative colitis 758
histocompatibility leukocyte antigen class I molecule; antigen presentation in hepatoma 897
history, natural
  hepatitis C and risk of severe liver disease (Review) 423
  low-grade reflux esophagitis 949
  management issues in hepatitis C (Review) 415
  of hepatocellular carcinoma (Review) 401
  of reflux esophagitis (Editorial) 1247
hormone, parathyroid; -related peptide and gastric motility 1260
human
  endothelin-3 and gallbladder contraction 324
  RNA telomerase; effect of on gastric carcinoma 1144
hydrogen breath test
  delayed gastrointestinal transit in hepatocellular carcinoma patients 1254
  glucose; gut-derived septicemia in strongyloidiasis (Case Report) 1331
hyperparathyroidism
  guidelines for management of acute pancreatitis (Working Party Report) S15
  hepatic artery calcification 91
hyperplasia, atypical adenomatous; hepatic nodules during computed tomography portography 779
hyperplastic polyp; evolution of colorectal cancer (Review) 17
hypersplenism
  effects of splenectomy on cirrhosis 77
  role of the spleen in liver fibrosis 59
hypertension
  idiopathic portal
    and scleroderma; overlap of (Case Report) 217
    non-alcoholic steatohepatitis (Review) 526
    non-cirrhotic portal fibrosis (Review) 6
    rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
  non-cirrhotic portal
  (Editorial) 1
    rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
    versus idiopathic portal (Review) S204
  portal
    carvedilol and propanolol in cirrhosis 183
    in children: an Indian perspective (Review) S228
    management of (Review) S439
    non-cirrhotic portal fibrosis (Review) 6
    novel approaches to treat (Review) S232
    pathology of fundic varices 1064
    refractory ascites and hepatorenal syndrome (Review) 456
    volume restitution in 1317
  portopulmonary, and hepatopulmonary syndrome (Review) S253
hypertensive
  gastropathy, portal; non-alcoholic steatohepatitis (Review) 526
  portal; drug therapy for acute bleeding in gastropathy 973

idiopathic portal hypertension
  and scleroderma; overlap of (Case Report) 217
  non-alcoholic steatohepatitis (Review) 526
  non-cirrhotic portal
    fibrosis
      by immunosensitization; rabbit model of 1312
      (Review) 6
    hypertension versus (Review) S204
ileoanal anastomosis; predictors of surgical outcomes S167
immune response
  oxymatrine anti-hepatitis B virus mechanism 1299
  Th1; gastric cancer (Review) 495
immunogenetics of hepatitis B virus infection (Review) S329
immunohistochemistry
  Fusobacterium varium in ulcerative colitis 849
  int-2 in colorectal carcinoma 1084
immunologic intervention in the pathogenesis, prophylaxis and therapeusis of hepatitis B (Review) S449
immunological tolerance
  new approaches for immunosuppression (Review) 116
  the liver effect (Review) S488
immunomodulating agents; management of hepatitis B virus S125
immunomodulation; cytokines in primary biliary cirrhosis 196
immunosuppression
  fibrosing cholestatic hepatitis (Case Report) 345
  new approaches for (Review) 116
immunotherapy; dendritic cell-based for hepatocellular carcinoma 889
incidence; newly developing hiatus hernia 542
incomplete septal cirrhosis; non-cirrhotic portal fibrosis (Review) 6
inducible nitric oxide; cyclo-oxygenase-2 and in pancreatic cancer 914
infection
  control; standards in endoscopy (Review) 361
  hepatitis C virus; in childhood (Review) 476
  mother-to-infant; different hepatitis C virus transmission in twins 617
  neonatal; hepatitis C in childhood (Review) 476
inflammation
  effect of IS-741 on experimental colitis 854
  Helicobacter pylori in reflux esophagitis 839
  mucosal; nuclear factor-κB activation of *Helicobacter pylori* 556, 1244
  prebiotic treatment of ulcerative colitis (Review) 818
inflammatory bowel disease
  bowel disease and inflammatory molecules (Editorial) 935
  Chlamydia pneumoniae and 987
  glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
  health-related quality of life and gastrointestinal disease S72
  lactoferrin reduces colitis in rats 1291

microscopic colitis 236
new therapies in S176
primary sclerosing cholangitis in Singapore 908
thalidomide in (Editorial) 233
inhibitor
cyclo-oxygenase-2; peptic ulcer disease (Review) 488
proton pump
gastro-oesophageal reflux disease: guidelines for clinicians (Special Report) 825
management of *Helicobacter pylori* infection (Review) 482
peptic ulcer disease (Review) 488
triple therapy with CYP2C19 748
urinary trypsin; in acute liver failure 140
injection therapy, ethanol; of isolated bile duct (Case Report) 807
instability
genetic; evolution of colorectal cancer (Review) 17
microsatellite; synchronous triple cancers of esophagus and stomach (Case Report) 724
insulin; steatosis in hepatitis C 873
insulin-like growth factor-binding protein-6; and Caco-2 cell proliferation 563
int-2; in colorectal carcinoma 1084
interferon
-α
alanine aminotransferase in hepatitis C virus combination therapy 1307
combination therapy for chronic hepatitis B virus 1087
lamivudine: clinical and economic outcomes 153
lymphoblastoid; prevention of hepatocellular carcinoma with (Review) S500
-γ
Fas and Fas ligand interaction 32
-producing cells; OK-Lipo prolongs survival of hepatocellular carcinoma in rats 81
regulation of tumor necrosis factor-γ-inducing apoptosis 1283
serum interleukin-18 and interleukin-10 levels in fulminant hepatic failure 285
hepatitis C advances in antiviral therapy (Review) 431
hepatocellular carcinoma in a responder to therapy (Case Report) 1229
management issues in hepatitis C (Review) 415
management of hepatitis C virus S146
non-responsive chronic hepatitis B 765
pegylated; management issues in hepatitis C (Review) 415
therapeutic vaccination in chronic hepatitis B 72
therapy; management of hepatitis B virus S125
treatment of chronic hepatitis B (Review) 409
with ribavirin for chronic hepatitis C 577
interleukin
-6; and angiogenic factor 1165
-10 and -18 levels in fulminant hepatic failure 285
bowel disease and inflammatory molecules (Editorial) 935
effect of geranylgeranlyacetone on interleukin-8 production 1153
lactoferrin reduces colitis in rats 1291
International Congress on Viral Hepatitis with the Participation of the World Health Organization, the International Agency for Research in Cancer and the International Atomic Energy Commission, Singapore 16–19 February 2000, Foreword S437
interstitial cells of Cajal; c-kit deficiency in diabetes mellitus 666
intestinal
absorption; jejunal bile acid 697
adaptation; dietary complexity and interstitial adaptation 1170
myectomy; ileo–ileal inhibitory reflex 1267
intestine
large, slow waves in; ileo–ileal inhibitory reflex 1267
small, electrical waves in; ileo–ileal inhibitory reflex 1267
intrahepatic, cholestasis; pediatric liver disease (Review) 521
intussusception (Images of Interest) 723
iron
deficiency
anemia; predictors for colorectal cancer 281
ferritin and *Helicobacter pylori* infection in children 754
overload disease; and hepatocellular carcinoma S192
irritable bowel syndrome
health-related quality of life and gastrointestinal disease S72
management of (Review) 503
prevalence of 1180
ischemic preconditioning; in rat liver 1211
isolated
bile duct; ethanol injection of (Case Report) 807
perfused rat liver; Kupffer cell phagocytosis in malaria 598

jaundice
and stones (Images of Interest) 1032
icteric type hepatocellular carcinoma 190

Ki-67 antigen; β-catenin expression in hepatocellular carcinoma 994
Kupffer cell; phagocytosis in malaria 598

lamivudine
clinical and economic outcomes 153
combination therapy for chronic hepatitis B virus 1087
fibrosing cholestatic hepatitis (Case Report) 345
interferon non-responsive chronic hepatitis B 765
management
of hepatitis B virus S125
of patients with chronic hepatitis B (Review) 406
therapy in patients with chronic hepatitis B, management of YMDD mutations during (Review) S333
treatment of chronic hepatitis B (Review) 409
laparoscopic colectomy; predictors of surgical outcomes S167
large
bowel diseases, 'developed society'; in Africans 249
intestine, slow waves in; ileo–ileal inhibitory reflex 1267
laser capture microdissection; synchronous triple cancers of esophagus and stomach (Case Report) 724
leak, bile; ethanol injection of isolated bile duct (Case Report) 807

lectin-reactive α-fetoprotein; and des-γ-carboxy prothrombin and hepatocellular carcinoma features, positivity of 772
lesions, mucosal; endoscopic mucosal resection (Review) 382
ligation
bile duct; opioids, nitric oxide and seizures 96
endoscopic
band; management of bleeding in cirrhotic patients (Review) 355
variceal; non-alcoholic steatohepatitis (Review) 526
lipid peroxidation; aldehydes do not directly activate hepatic stellate cells 785
lipoprotein, high-density; scavenger receptor class B type 1 in gallbladder 713
liposome-encapsulated OK-432; prolongs survival of hepatocellular carcinoma in rats 81
lithostathine; role of oxyradicals in chronic pancreatitis 606
liver
abscess, pyogenic; over 10 years 1001
aldehydes do not directly activate hepatic stellate cells 785
assist device, albumin dialysis-based extracorporeal: molecular adsorbent recirculating system (Review) S280
biopsy
hepatitis C in childhood (Review) 476
non-alcoholic fatty liver disease S186
cirrhosis
cyclo-oxygenase-2 in hepatitis and hepatocellular carcinoma 1110
effects of splenectomy on cirrhosis 77
hepatitis B viral genotypes 643
hepatogenous diabetes in 677
Stronger Neo-Minophagen C for chronic hepatitis 1198
disease
and hepatitis
in Hong Kong (Review) S510
in Indonesia (Review) S508
cholestatic; hepatic transport systems S105
chronic
antituberculosis drugs in patients with (Review) S408
cholestatic (Review) S399
hepatitis B and C in New Zealand 582
hepatitis B virus genotypes in India 165
scoring severity of (Review) S298
copper metabolic defects and: environmental aspects (Review) S403
end-stage; malnutrition and bone disease in cirrhosis patients (Review) 462
in India
herbal medicine for (Review) S370
history (Review) S504
metabolic; pediatric (Review) 521
non-alcoholic fatty, treatment of (Review) S385
effect; immunological tolerance (Review) S488
failure, acute; pediatric (Review) 521
fatty
non-alcoholic and non-obese 1098
non-alcoholic fatty liver disease (Review) 1136
steatosis in hepatitis C 873
fibrosis; role of the spleen in 59
fluke infestation; cholangiocarcinoma (Review) 1049
granulomatous phlebitis of; (Case Report) 1334
ischemic preconditioning in rat 1211
isolated perfused rat; Kupffer cell phagocytosis in malaria 598
metastasis from colon cancer successfully treated by regional chemotherapy with mitomycin C alone, case of (Letter to the Editor) 227
new approaches for immunosuppression (Review) 116
not receiving portal vein blood, subcapsular region of (Images of Interest) 1330, 1340
reversal of cirrhosis by TAK-044 589
tests; hypoxemia and cirrhosis 1106
transplantation
and disease recurrence (Editorial) 733
disease recurrence after 203
in cystic fibrosis 208
malnutrition and bone disease in cirrhosis patients (Review) 462
refractory ascites and hepatorenal syndrome (Review) 456
retroviral gene transfer to the rat liver graft 1008 (Review) S294
treatment of alcoholic hepatitis (Review) 448
volume; effects of splenectomy on cirrhosis 77
logistic analysis; factors affecting endoscopic mucosal resection 845
longitudinal ulcer; Behçet's colitis resembling Crohn's disease (Case Report) 105
loss of heterozygosity; and hypermethylation at *p14*^{ARF} in hepatocellular carcinoma 301
low dietary fiber intake; large bowel disease in Africans 249
lupus-like syndrome; autoantibody with chronic hepatitis C (Case Report) 927
lymph node metastasis; hepatic carcinoid tumor with (Case Report) 1119
lymphocyte
stimulating test; fulminant hepatic failure associated with benzbromarone treatment (Letter to the Editor) 625
tumor-infiltrating; Fas and Fas ligand interaction 32
lymphocytic colitis; microscopic 236
lymphoma
MALToma versus marginal zone versus diffuse large B cell (Letter to the Editor and Reply) 226
mucosa-associated lymphoid tissue; synchronous gastric tumors (Case Report) 1033

magnified views of normal
corpus; *Helicobacter pylori*-free stomach 39
pyloric mucosa; *Helicobacter pylori*-free stomach 39
malabsorption, carbohydrate; large bowel disease in Africans 249
malaria phagocytosis; Kupffer cell phagocytosis in 598
malignancy; pyogenic liver abscess over 10 years 1001
malnutrition; and bone disease in cirrhosis patients (Review) 462
malondialdehyde; aldehydes do not directly activate hepatic stellate cells 785
MALToma versus marginal zone lymphoma versus diffuse large B cell lymphoma (Letter to the Editor and Reply) 226

management
chronic pancreatitis consensus report (Review) 508
consensus; of patients with chronic hepatitis B (Review) 406
of hepatic encephalopathy (Review) S260
of portal hypertension (Review) S439
of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B (Review) S333
refractory ascites and hepatorenal syndrome (Review) 456
total quality; infection control standards in endoscopy (Review) 361
manual cleansing; infection control standards in endoscopy (Review) 361
marginal ulcer; endoscopic for a bleeding 1220
Markov modeling; hepatitis C and risk of severe liver disease (Review) 423
mass, body cell; malnutrition and bone disease in cirrhosis patients (Review) 462
maternal transmission; hepatitis C in childhood (Review) 476
meal
fatty; and hepatic clearance 337
test; [^{13}C]-urea breath test protocol for Chinese 834
mechanisms
molecular, of hepatitis virus–hepatocyte interactions (Review) S342
of drug resistance and novel approaches to therapy for chronic hepatitis C (Review) S351
pathophysiological; management of irritable bowel syndrome (Review) 503
medical practice; shepherds of science (Editorial) 816
medicine, evidence-based, in the treatment of hepatocellular carcinoma (Review) S428
medium-chain triglycerides; treatment of alcoholic hepatitis (Review) 448
membrane, basement; collagen a (IV) chains in colon cancer 980
messenger RNA, glucocorticoid receptor; glucocorticoid receptor in Crohn's disease lymphocytes 1070
metabolic
bone disease; and malnutrition in cirrhosis patients (Review) 462
defects, copper, and liver disease: environmental aspects (Review) S403
liver disease; pediatric (Review) 521
metastasis
lymph node; hepatic carcinoid tumor with (Case Report) 1119
neoplasm; β-catenin expression in hepatocellular carcinoma 994
methemoglobin; carbon monoxide and abdominal surgery 535
methylation, promoter; hypermethylation and loss of heterozygosity at *p14^{ARF}* in hepatocellular carcinoma 301
metronidazole; management of *Helicobacter pylori* infection (Review) 482
microcirculation
Helicobacter pylori and gastric ulcer angiogenesis 960
hepatic; retinoids in hepatic fibrosis 791
ischemic preconditioning in rat liver 1211
microdissection, laser capture; synchronous triple cancers of esophagus and stomach (Case Report) 724
microflora
mucosal; *Fusobacterium varium* in ulcerative colitis 849
prebiotic treatment of ulcerative colitis (Review) 818
microsatellite instability; synchronous triple cancers of esophagus and stomach (Case Report) 724
microscopic colitis 236
microscopy
confocal laser scanning; 3-D examination of hepatic stellate cells 861
fluorescence; retinoids in hepatic fibrosis 791
microsphere, radioactive; volume restitution in portal hypertension 1317
mitochondrial antibody, enzymatic; enzyme inhibition assay in primary biliary cirrhosis 316
model, animal; rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
modeling, Markov; hepatitis C and risk of severe liver disease (Review) 423
molecular
adsorbent recirculating system: albumin dialysis-based extracorporeal liver assist device (Review) S280
characterization of hepatitis B surface antigen mutants in Singapore patients (Review) S491
epidemiology; hepatitis B viral genotypes 643
mechanisms of hepatitis virus–hepatocyte interactions (Review) S342
monochorionic diamniotic monozygous twins; different hepatitis C virus transmission in 617
monoclonal antibodies; new technologies for endoscopic diagnosis S85
mononuclear cells, peripheral-blood; glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
monozygous twins, monochorionic diamniotic; different hepatitis C virus transmission in twins 617
mortality; treatment of alcoholic hepatitis (Review) 448
mother-to-infant infection; different hepatitis C virus transmission in twins 617
motility
esophageal; low-grade reflux esophagitis 949
gallbladder; endothelin-3 and gallbladder contraction 324
gastric; parathyroid hormone-related peptide and 1260
gastrointestinal; gut dysmotility: a new classification (Working Party Report) S1
gut; ileo–ileal inhibitory reflex 1267
motor disorders; gut dysmotility: a new classification (Working Party Report) S1
mouse
Helicobacter pylori promotes gastric carcinogenesis 253
model; dysplasia–carcinoma in ulcerative colitis 1078
opioids, nitric oxide and seizures 96
transgenic
oxymatrine anti-hepatitis B virus mechanism 1299
role of hepatitis C virus in development of hepatocellular carcinoma (Review) 394
scavenger receptor class B type 1 in gallbladder 713
mucin-hypersecreting neoplasms of the bile duct (Images of Interest) 924
mucosa
Barrett's; prevention and treatment of dysplasia in gastroesophageal reflux disease S113
magnified views of normal pyloric; *Helicobacter pylori*-free stomach 39

mucosa-associated lymphoid tissue lymphoma; synchronous gastric tumors (Case Report) 1033
mucosal
IgA deposition in Henoch–Schönlein purpura with duodenal ulcer (Letter to the Editor) 728
inflammation; nuclear factor-κB activation of *Helicobacter pylori* 556, 1244
lesions; endoscopic resection (Review) 382
microflora; *Fusobacterium varium* in ulcerative colitis 849
resection, endoscopic; factors affecting 845
tissue injury; effect of geranylgeranlyacetone on interleukin-8 production 1153
multidisciplinary approach; management of bleeding in cirrhotic patients (Review) 355
multimodality treatment; esophageal cancer in the Asia–Pacific region (Review) 374
mutant, precore; hepatitis B virus genotypes in Thailand 671
mutation
gene; genetic testing for colorectal cancer (Review) 389
YMDD, management of during lamivudine therapy in patients with chronic hepatitis B (Review) S333
myectomy, intestinal; ileo–ileal inhibitory reflex 1267
myeloma; iron-deficiency anemia complicating AL amyloidosis (Case Report) 623

naltrexone; opioids, nitric oxide and seizures 96
natural
history
hepatitis C and risk of severe liver disease (Review) 423
low-grade reflux esophagitis 949
management issues in hepatitis C (Review) 415
of hepatocellular carcinoma (Review) 401
of reflux esophagitis (Editorial) 1247
killer cells; OK-Lipo prolongs survival of hepatocellular carcinoma in rats 81
near patient test; for *Helicobacter pyloriI* 1272
neoadjuvant therapy; predicting response in gastrointestinal cancer therapy S172
neonatal infection; hepatitis C in childhood (Review) 476
neoplasm
esophageal; cancer in the Asia–Pacific region (Review) 374
metastasis; β-catenin expression in hepatocellular carcinoma 994
mucin-hypersecreting; of the bile duct (Images of Interest) 924
nervous
activity, autonomic; in endoscopic retrograde cholangiopancreatography 1021
system, enteric; management of irritable bowel syndrome (Review) 503
neuron-specific enolase; hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
neutrophil activation; effect of geranylgeranlyacetone on interleukin-8 production 1153
new enzyme immunoassay for the detection of antibody to hepatitis E virus (Review) S360
nitrate; and nitrite, detection of in primary biliary cirrhosis 308
nitric oxide
carbon monoxide
and abdominal surgery 535
hemoglobin, a stress-induced marker (Editorial) 519
detection of nitrite and nitrate in primary biliary cirrhosis 308
inducible; cyclo-oxygenase-2 and in pancreatic cancer 914
opioids, and seizures 96
synthase; detection of nitrite and nitrate in primary biliary cirrhosis 308
nitrite; and nitrate, detection of in primary biliary cirrhosis 308
N-methyl-*N*-nitrosourea; *Helicobacter pylori* promotes gastric carcinogenesis 253
nodule, hepatic; during computed tomography portography 779
nodule-in-nodule hepatocellular carcinoma; hepatic computed tomography portography 779
non-alcoholic
fatty liver disease, treatment of (Review) S385
steatohepatitis
non-alcoholic fatty liver disease (Review) 1136, S186
definitions and pathogenesis (Review) S377
non-cirrhotic
portal fibrosis
non-alcoholic steatohepatitis (Review) 526
rabbit model by immunosensitization 1312
(Review) 6, S214
portal hypertension
(Editorial) 1
rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
versus idiopathic portal hypertension (Review) S204
non-English-speaking background; hepatitis C, general practitioners 295
non-polyposis colorectal cancer, hereditary
evolution of (Review) 17
genetic testing for (Review) 389
non-resectable hepatocellular carcinoma, treatment of (Review) S424
non-responders to interferon; chronic hepatitis B 765
non-response to antiviral therapy; management issues in hepatitis C (Review) 415
non-steroidal anti-inflammatory drugs; peptic ulcer disease (Review) 488
non-structural proteins; advances in hepatitis C (Review) 442
novel approaches
to therapy for chronic hepatitis C, mechanisms of drug resistance and (Review) S351
to treat portal hypertension (Review) S232
nuclear factor-κB; activation of *Helicobacter pylori* 556, 1244
nutritional
assessment; malnutrition and bone disease in cirrhosis patients (Review) 462
therapy; treatment of alcoholic hepatitis (Review) 448

octreotide; drug therapy for acute bleeding in portal hypertensive gastropathy 973
OK-432, liposome-encapsulated; prolongs survival of hepatocellular carcinoma in rats 81
old woman with stones and jaundice (Images of Interest) 1032

omeprazole
drug therapy for acute bleeding in portal hypertensive gastropathy 973
reflux esophagitis and proton pump inhibitor 955
oncogenes; molecular pathology and gastric carcinoma 966
orocecal transit time; delayed gastrointestinal transit in hepatocellular carcinoma patients 1254
osteopenia; extrahepatic manifestations of cholestasis (Review) 938
osteoporosis, extrahepatic manifestations of cholestasis (Review) 938
outcome, clinical
hepatitis
B viral genotypes 643
C
in childhood (Review) 476
risk of severe liver disease (Review) 423
oxidative stress and hepatic stellate cells (Editorial) 1045
oxygenase, heme; carbon monoxide hemoglobin, a stress-induced marker (Editorial) 519
oxymatrine anti-hepatitis B virus mechanism 1299

p14; hypermethylation and loss of heterozygosity in hepatocellular carcinoma 301
p16; hypermethylation and loss of heterozygosity at $p14^{ARF}$ in hepatocellular carcinoma 301
p53; cholangiocarcinoma (Review) 1056
pain, recurrent abdominal; psychosocial factors and (Review) 1250
pancreatic
cancer; cyclo-oxygenase-2 and inducible nitric oxide synthase in 914
replacement therapy; chronic pancreatitis consensus report (Review) 508
pancreatitis
acute
guidelines for management of (Working Party Report) S15
hemolytic uremic syndrome and whole splenic infarction (Letter to the Editor) 1040
alcoholic chronic; metabolic genotypes in cirrhosis and 177
chronic
consensus report (Review) 508
role of oxyradicals in 606
tropical; consensus report (Review) 508
paraneoplastic syndrome; dermatomyositis and erythrocytosis (Letter to the Editor) 1239
parathormone; hepatic artery calcification 91
parathyroid hormone-related peptide and gastric motility 1260
parietal cells; cell renewal of stomach 262
pathogenesis
and definitions of non-alcoholic steatohepatitis (Review) S377
Escherichia coli and diarrhea (Review) 467
gastric cancer (Review) 495
immunologic intervention in the, prophylaxis and therapeusis of hepatitis B (Review) S449
of ascites and predictors of resistance to therapy (Review) S242
of hepatic encephalopathy (Review) S256
viral, of hepatocellular carcinoma (Review) S413
pathology, biliary; pyogenic liver abscess over 10 years 1001
pathophysiological mechanisms; management of irritable bowel syndrome (Review) 503
pathophysiology
of portal hypertension (Review) S482
refractory ascites and hepatorenal syndrome (Review) 456
patient
test, near; for *Helicobacter pyloriI* 1272
treatment-naïve; interferon with ribavirin for chronic hepatitis C 577
pattern, symptom; management of irritable bowel syndrome (Review) 503
pegylated interferon; management issues in hepatitis C (Review) 415
pentoxifylline; treatment of alcoholic hepatitis (Review) 448
pentylenetetrazole; opioids, nitric oxide and seizures 96
peptic ulcer
disease (Review) 488
Helicobacter pylori
and gastric ulcer angiogenesis 960
in India 659
percentage body fat; non-alcoholic and non-obese fatty liver 1098
percutaneous
endoscopic gastrostomy; buried bumper syndrome (Case Report) 1125
ethanol injection; prognostic factors of 1205
perforation; endoscopic mucosal resection (Review) 382
peribiliary gland; cholangiocarcinoma (Review) 1056
peripheral-blood mononuclear cells; glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
peritonitis; carbon monoxide and abdominal surgery 535
peroxidation, lipid; aldehydes do not directly activate hepatic stellate cells 785
Peutz-Jegher's syndrome
genetic testing for colorectal cancer (Review) 389
(Images of Interest) 1117
phagocytosis, Kupffer cell; malaria 598
pharmacological treatment; management of irritable bowel syndrome (Review) 503
phenylmethylsulfonyl fluoride; regulation of tumor necrosis factor- and interferon-γ-inducing apoptosis 1283
phenytoin; and cytomegalovirus ileitis (Letter to the Editor) 1240
phlebitis of the liver, granulomatous (Case Report) 1334
phylogeny; hepatitis B virus genotypes in Thailand 671
Plasmodium berghei; Kupffer cell phagocytosis in malaria 598
polyethylene glycol–interferon: current status in hepatitis C virus therapy (Review) S344
polymerase
advances in hepatitis C (Review) 442
chain reaction, competitive; glucocorticoid receptor messenger RNA in Crohn's disease lymphocytes 1070
polyp
detection; virtual colonoscopy in Chinese 1323
fundic gland; south-east Scotland 1161
hyperplastic; evolution of colorectal cancer (Review) 17

polyposis
familial adenomatous; genetic testing for colorectal cancer (Review) 389
south-east Scotland fundic gland polyps 1161
population
attributable risk; hepatitis B and C in chronic liver disease in New Zealand 582
gallstone prevalence in Western Siberia 702
porcelain gallbladder (Images of Interest) 1228
portal
fibrosis
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic (Review) 6, S214
rabbit model by immunosensitization 1312
hypertension
carvedilol and propanolol in cirrhosis 183
idiopathic
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic portal fibrosis (Review) 6
overlap with scleroderma (Case Report) 217
rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
in children: an Indian perspective (Review) S228
management of (Review) S439
non-cirrhotic (Editorial) 1
non-cirrhotic portal fibrosis (Review) 6
novel approaches to treat (Review) S232
pathology of fundic varices 1064
pathophysiology of (Review) S482
rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
refractory ascites and hepatorenal syndrome (Review) 456
versus idiopathic portal hypertension (Review) S204
volume restitution in 1317
hypertensive
gastropathy
drug therapy for acute bleeding in 973
non-alcoholic steatohepatitis (Review) 526
pressure; rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
vein
blood, subcapsular region of the liver not receiving (Images of Interest) 1330, 1340
obstruction, extrahepatic
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic portal fibrosis (Review) 6
thrombosis, spectrum of in the West (Review) S224
portography, computed tomography; hepatic nodules during 779
portopulmonary hypertension and hepatopulmonary syndrome (Review) S253
portosystemic shunts; non-cirrhotic portal fibrosis (Review) 6
possum; endothelin-3 and gallbladder contraction 324
post-therapy care; endoscopic mucosal resection (Review) 382
practice
general; hepatitis C, general practitioners 295
medical; shepherds of science (Editorial) 816
prebiotics; treatment of ulcerative colitis (Review) 818
precancerous lesion; cholangiocarcinoma (Review) 1056
preconditioning, ischemic; in rat liver 1211
precore mutant; hepatitis B virus genotypes in Thailand 671
predictive factors; for colorectal cancer 281
pressure
colonic dsymotility in constipation 270
portal; rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
prevalence
gallstone; in Western Siberia 702
Helicobacter pylori infection in athletes 131
hepatitis B and C in chronic liver disease in New Zealand 582
of cholelithiasis in the general population at Chandigarh in northern India (Letter to the Editor) 1343
of irritable bowel disease 1180
prevention of hepatocellular carcinoma with lymphoblastoid α interferon (Review) S500
primary
amyloidosis, gastrocolic fistula complicating (Letter to the Editor) 110
biliary cirrhosis
cytokines in 196
detection of nitrite and nitrate in 308
efficacy of colestimide in cholestasis (Editorial) 1133
enzyme inhibition assay in 316
care; near patient test for *Helicobacter pylori* 1272
hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
sclerosing cholangitis; in Singapore 908
priming, corticosteroid; management of patients with chronic hepatitis B (Review) 406
probe, heater; endoscopic for a bleeding marginal ulcer 1220
prognosis
hepatogenous diabetes in liver cirrhosis 677
of percutaneous ethanol injection 1205
serum interleukin-18 and interleukin-10 levels in fulminant hepatic failure 285
terlipressin in type 1 hepatorenal syndrome 882
progression
disease; hepatitis C and risk of severe liver disease (Review) 423
from chronic hepatitis to hepatocellular carcinoma: natural course and treatments (Review) S434
proliferating cell nuclear antigen; *Helicobacter pylori* promotes gastric carcinogenesis 253
proliferation
cellular; insulin-like growth factor-binding protein-6 and Caco-2 563
cyclo-oxygenase-2 and inducible nitric oxide synthase in pancreatic cancer 914
promoter methylation; hypermethylation and loss of heterozygosity at $p14^{ARF}$ in hepatocellular carcinoma 301
propanolol; and carvedilol in cirrhosis 183
prophylaxis
and epidemiology of viral hepatitis S155
immunologic intervention in the pathogenesis and therapeusis of hepatitis B (Review) S449
propylthiouracil; treatment of alcoholic hepatitis (Review) 448
prostaglandin; gastric slow-wave dysrhythmia 46
protease; advances in hepatitis C (Review) 442

protein
-6, insulin-like growth factor-binding; and Caco-2 cell proliferation 563
core; role of hepatitis C virus in development of hepatocellular carcinoma (Review) 394
glial fibrillary acidic; 3-D examination of hepatic stellate cells 861
non-structural; advances in hepatitis C (Review) 442
prothrombin, des-γ-carboxy; and lectin-reactive α-fetoprotein, positivity of, and hepatocellular carcinoma features 772
proton pump inhibitor
gastro-oesophageal reflux disease: guidelines for clinicians (Special Report) 825
in triple therapy with *CYP2C19* 748
management of *Helicobacter pylori* infection (Review) 482
peptic ulcer disease (Review) 488
pruritus; extrahepatic manifestations of cholestasis (Review) 938
pseudo-obstruction; iron-deficiency anemia complicating AL amyloidosis (Case Report) 623
psoriasis, acute hepatitis induced by traditional Chinese herbs used in the treatment of (Letter to the Editor) 1342
psychological approaches; management of irritable bowel syndrome (Review) 503
psychosocial factors; and abdominal pain (Review) 1250
public health measures in the control of viral hepatitis (Review) S452
pyloric mucosa, magnified views of normal; *Helicobacter pylori*-free stomach 39
pyogenic liver abscess; over 10 years 1001
pyruvate dehydrogenase complex; enzyme inhibition assay in primary biliary cirrhosis 316

quadruple therapy; management of *Helicobacter pylori* infection (Review) 482
quality of life; of rectal cancer patients 571

radioactive microsphere; volume restitution in portal hypertension 1317
radiotherapy; icteric type hepatocellular carcinoma 190
ranitidine bismuth citrate; management of *Helicobacter pylori* infection (Review) 482
rat
Gunn; function of immortalized hepatocytes *in vivo* 690
liver, isolated perfused; Kupffer cell phagocytosis in malaria 598
retinoids in hepatic fibrosis 791
receptor
antagonists, histamine; peptic ulcer disease (Review) 488
parathyroid hormone-related peptide and gastric motility 1260
reversal of cirrhosis by TAK-044 589
soluble tumor necrosis factor; regulation of tumor necrosis factor- and interferon-γ-inducing apoptosis 1283
recommendations
and summary of single theme conferences on hepatitis B and C S197
consensus; chronic pancreatitis report (Review) 508
rectal
bleeding; predictors for colorectal cancer 281
cancer
quality of life of 571
surgery; predictors of surgical outcomes S167
recto-colic; colonic dsymotility in constipation 270
rectum
colonic dsymotility in constipation 270
iron-deficiency anemia complicating AL amyloidosis (Case Report) 623
recurrence
disease; after liver transplantation 203
of hepatocellular carcinoma following transcatheter arterial chemoembolization 52
recurrent abdominal pain; psychosocial factors and (Review) 1250
reflex; colonic dsymotility in constipation 270
reflux
disease; health-related quality of life and gastrointestinal disease S72
esophagitis
and proton pump inhibitor 955
Helicobacter pylori in 839
low-grade 949
natural history of (Editorial) 1247
refractory ascites and hepatorenal syndrome (Review) 456
regeneration, hepatic; role of the spleen in liver fibrosis 59
regular arrangement of collecting venules; *Helicobacter pylori*-free stomach 39
reinfection rate of *Helicobacter pylori* 27
rejection, graft; new approaches for immunosuppression (Review) 116
relapse; management issues in hepatitis C (Review) 415
renal failure
hepatic artery calcification 91
hepatorenal syndrome in cirrhosis 739
replacement therapy, pancreatic; chronic pancreatitis consensus report (Review) 508
reprocessors, endoscope; infection control standards in endoscopy (Review) 361
resection
endoscopic mucosal
factors affecting 845
(Review) 382
small bowel; dietary complexity and interstitial adaptation 1170
resin, anion-exchange; jejunal bile acid absorption 697
resistance, bacterial; management of *Helicobacter pylori* infection (Review) 482
response
immune; oxymatrine anti-hepatitis B virus mechanism 1299
sustained viral
alanine aminotransferase in hepatitis C virus combination therapy 1307
hepatitis C advances in antiviral therapy (Review) 431
management issues in hepatitis C (Review) 415
Th1 immune; gastric cancer (Review) 495
retrovirus; retroviral gene transfer to the rat liver graft 1008

ribavirin
alanine aminotransferase in hepatitis C virus combination therapy 1307
hepatitis C advances in antiviral therapy (Review) 431
interferon with for chronic hepatitis C 577
management
issues in hepatitis C (Review) 415
of hepatitis C virus S146
risk
factor
different hepatitis C virus transmission in twins 617
hepatitis C
in Iranian donors 1092
in childhood (Review) 476
disease, health-related quality of life and gastrointestinal disease S72
population attributable; hepatitis B and C in chronic liver disease in New Zealand 582
testing for hemochromatosis 800
RNA, 16S ribosomal; granulomatous phlebitis (Case Report) 1334
role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: basis for primary prevention (Review) S441
Rome II criteria; prevalence of irritable bowel disease 1180
rupture, variceal; pathology of fundic varices 1064

S-adenosyl-methionine; treatment of alcoholic hepatitis (Review) 448
s-antigen; hepatitis B virus genotypes in India 165
safety, technology; infection control standards in endoscopy (Review) 361
scavenger receptor class B type 1 in gallbladder 713
scleroderma; overlap of idiopathic portal hypertension and (Case Report) 217
sclerosing cholangitis, primary; in Singapore 908
sclerosis, hepatoportal; non-cirrhotic portal fibrosis (Review) 6
sclerotherapy, endoscopic
management of bleeding in cirrhotic patients (Review) 355
non-alcoholic steatohepatitis (Review) 526
non-cirrhotic portal fibrosis (Review) 6
score, symptom; Hong Kong index of dyspepsia 545
scoring severity of chronic liver disease (Review) S298
screening
endoscopic; genetic testing for colorectal cancer (Review) 389
testing for hemochromatosis 800
secondary care; near patient test for *Helicobacter pylori* 1272
seizure threshold, clonic; opioids, nitric oxide and 96
sensation; colonic dsymotility in constipation 270
septal cirrhosis, incomplete; non-cirrhotic portal fibrosis (Review) 6
seropositivity; positivity of lectin-reactive α-fetoprotein, des-γ-carboxy prothrombin and hepatocellular carcinoma features 772
serum antibody; *Fusobacterium varium* in ulcerative colitis 849
severity of chronic liver disease, scoring (Review) S298
short bowel syndrome; dietary complexity and interstitial adaptation 1170
shunt
surgery; non-alcoholic steatohepatitis (Review) 526
portosystemic; non-cirrhotic portal fibrosis (Review) 6
Siberia; gallstone prevalence in Western 702
silymarin; treatment of alcoholic hepatitis (Review) 448
situs inversus viscerum (Images of Interest) 1329
slow waves in large intestine; ileo–ileal inhibitory reflex 1267
small
bowel
bacterial overgrowth; gut-derived septicemia in strongyloidiasis (Case Report) 1331
resection; dietary complexity and interstitial adaptation 1170
intestine, electrical waves in; ileo–ileal inhibitory reflex 1267
smooth muscle cells; cell renewal of stomach 262
soluble tumor necrosis factor receptors; regulation of and interferon-γ-inducing apoptosis 1283
somatostatin analogs; management of bleeding in cirrhotic patients (Review) 355
spectrum of portal vein thrombosis in the West (Review) S224
sphincterotomy, endoscopic; fatty meal and hepatic clearance 337
splenectomy
carbon monoxide and abdominal surgery 535
effects of on cirrhosis 77
splenic artery; hepatic artery calcification 91
splenoportovenography; non-cirrhotic portal fibrosis (Review) 6
squamous cell carcinoma; esophageal cancer in the Asia–Pacific region (Review) 374
stain
Grimelius; hepatic carcinoid tumor with lymph node metastasis (Case Report) 1119
tumor; prognostic factors of percutaneous ethanol injection 1205
steatohepatitis, non-alcoholic
definitions and pathogenesis (Review) S377
non-alcoholic fatty liver disease S186
non-alcoholic fatty liver disease (Review) 1136
stellate cell, hepatic
aldehydes do not directly activate 785
and oxidative stress (Editorial) 1045
stem cells: a dramatic new therapeutic tool (Review) 636
stoma; quality of life of rectal cancer patients 571
stomach
endoscopic finding of normal; *Helicobacter pylori*-free 39
vascular lesions of the (Images of Interest) 621
strain, drug-resistant; hepatitis B surface gene variation (Editorial) 933
S-transferases, glutathione; metabolic genotypes in cirrhosis and pancreatitis 177
stress; parathyroid hormone-related peptide and gastric motility 1260
stromal cell tumor, gastrointestinal; synchronous gastric tumors (Case Report) 1033
study, experimental; shepherds of science (Editorial) 816
subcapsular region of the liver not receiving portal vein blood (Images of Interest) 1330, 1340
subtype; hepatitis B viral genotypes 643

summary and recommendations of single theme conferences on hepatitis B and C S197
superinfection; hepatitis B viral genotypes 643
superoxide dismutase; role of oxyradicals in chronic pancreatitis 606
surgery
apoptosis in ulcerative colitis 758
esophageal cancer in the Asia–Pacific region (Review) 374
for hepatocellular carcinoma (Review) S421
rectal cancer; predictors of surgical outcomes S167
shunt; non-alcoholic steatohepatitis (Review) 526
survival
disease recurrence after liver transplantation 203
rate; hypoxemia and cirrhosis 1106
sustained viral response
alanine aminotransferase in hepatitis C virus combination therapy 1307
hepatitis C advances in antiviral therapy (Review) 431
management issues in hepatitis C (Review) 415
symptom
bowel; predictors for colorectal cancer 281
patterns; management of irritable bowel syndrome (Review) 503
relief rate; reflux esophagitis and proton pump inhibitor 955
score; Hong Kong index of dyspepsia 545
synchronous triple cancers of esophagus and stomach (Case Report) 724
synthase, nitric oxide; detection of nitrite and nitrate in primary biliary cirrhosis 308

T helper cell 1 and 2 cytokine; oxymatrine anti-hepatitis B virus mechanism 1299
tea consumption and *Helicobacter* 552
technology
diagnostic; gut dysmotility: a new classification (Working Party Report) S1
safety; infection control standards in endoscopy (Review) 361
telomerase, human RNA; effect on gastric carcinoma 1144
tendency, familial; mortality in hepatocellular carcinoma families 682
terlipressin; in type 1 hepatorenal syndrome 882
test
and treat; near patient test for *Helicobacter pyloriI* 1272
meal; [^{13}C]-urea breath test protocol for Chinese 834
testing, genetic; for colorectal cancer (Review) 389
Th1 immune response; gastric cancer (Review) 495
thalidomide
in inflammatory bowel disease 135
in inflammatory bowel disease (Editorial) 233
therapeusis; immunologic intervention in the pathogenesis and prophylaxis of hepatitis B (Review) S449
therapy
anti-oxidant; treatment of alcoholic hepatitis (Review) 448
antiviral
hepatitis C advances in (Review) 431
non-response to; management issues in hepatitis C (Review) 415
changing role of endoscopy (Review) 369
combination
for chronic hepatitis B virus 1087
hepatitis B virus; interferon non-responsive chronic hepatitis B 765
management issues in hepatitis C (Review) 415
treatment of chronic hepatitis B (Review) 409
endoscopic
chronic pancreatitis consensus report (Review) 508
esophageal cancer in the Asia–Pacific region (Review) 374
eradication; reinfection rate of *Helicobacter pylori* 27
ethanol injection of isolated bile duct (Case Report) 807
for chronic hepatitis B, combination and newer (Review) S338
gene
effect of antisense telomerase RNA on gastric carcinoma 1144
retroviral gene transfer to the rat liver graft 1008
interferon; management of hepatitis B virus S125
neoadjuvant; predicting response in gastrointestinal cancer S172
nutritional; treatment of alcoholic hepatitis (Review) 448
pancreatic replacement; chronic pancreatitis consensus report (Review) 508
pathogenesis of ascites and predictors of resistance to (Review) S242
polyethylene glycol–interferon: current status in hepatitis C virus (Review) S344
quadruple; management of *Helicobacter pylori* infection (Review) 482
triple
management of *Helicobacter pylori* infection (Review) 482
proton pump inhibitor with *CYP2C19* 748
thermocoagulation; endoscopic for a bleeding marginal ulcer 1220
threshold, clonic seizure; opioids, nitric oxide and seizures 96
thrombosis in the West, spectrum of portal vein (Review) S224
T-lymphocytes, cytotoxic; antigen presentation in hepatoma 897
tolerance, immunological; new approaches for immunosuppression (Review) 116
total quality management; infection control standards in endoscopy (Review) 361
tracheal involvement from esophageal cancer (Images of Interest) 215
transarterial chemoembolization; icteric type hepatocellular carcinoma 190
transcatheter arterial chemoembolization
gastric slow-wave dysrhythmia 46
hepatocellular carcinoma treated with (Images of Interest) 104
recurrence of hepatocellular carcinoma following 52
transforming growth factor-b
-1; role of the spleen in liver fibrosis 59
cholangiocarcinoma (Review) 1056
cytokines in primary biliary cirrhosis 196
transgenic mouse
oxymatrine anti-hepatitis B virus mechanism 1299

role of hepatitis C virus in development of hepatocellular carcinoma (Review) 394
scavenger receptor class B type 1 in gallbladder 713
transit
gastrointestinal; delayed in hepatocellular carcinoma patients 1254
time, orocecal; delayed gastrointestinal, in hepatocellular carcinoma patients 1254
transjugular intrahepatic portasystemic shunt
management of bleeding in cirrhotic patients (Review) 355
refractory ascites and hepatorenal syndrome (Review) 456
transmission, maternal; hepatitis C in childhood (Review) 476
transpapillary biopsy; endothelin-3 and gallbladder contraction 324
transplantation
hepatocyte
function of immortalized hepatocytes in vivo 690 (Review) S287
liver
and disease recurrence (Editorial) 733
disease recurrence after 203
in cystic fibrosis 208
malnutrition and bone disease in cirrhosis patients (Review) 462
refractory ascites and hepatorenal syndrome (Review) 456
retroviral gene transfer to the rat liver graft 1008 (Review) S294
treatment of alcoholic hepatitis (Review) 448
new approaches for immunosuppression (Review) 116
treat, test and; near patient test for *Helicobacter pylori* 1272
treatment
antiviral, of
chronic hepatitis B (Review) 409
patients with hepatitis B virus-related cirrhosis (Review) S306
course; of chronic hepatitis B (Review) 409
curative; endoscopic mucosal resection (Review) 382
hepatitis
B: weighing the costs of (Editorial) 737
C in childhood (Review) 476
multimodality; esophageal cancer in the Asia–Pacific region (Review) 374
-naive patients; interferon with ribavirin for chronic hepatitis C 577
of
alcoholic hepatitis (Review) 448
non-alcoholic fatty liver disease (Review) S385
non-resectable hepatocellular carcinoma (Review) S424
patients with hepatic failure (Review) S274
pharmacological; management of irritable bowel syndrome (Review) 503
success; management of Helicobacter pylori infection (Review) 482
therapeutic vaccination in chronic hepatitis B 72
triglyceride
medium-chain; treatment of alcoholic hepatitis (Review) 448
steatosis in hepatitis C 873
triple therapy
management of *Helicobacter pylori* infection (Review) 482
proton pump inhibitor with CYP2C19 748
tritiated thymidine autoradiography; cell renewal of stomach 262
tropical pancreatitis; chronic pancreatitis consensus report (Review) 508
trypsin inhibitor, urinary; in acute liver failure 140
TT virus; in a hepatitis C virus/hepatitis B virus endemic township 1192
tumor necrosis factor
-α
and interferon-γ-inducing apoptosis, regulation of 1283
cytokines in primary biliary cirrhosis 196
lactoferrin reduces colitis in rats 1291
-receptor type 1; and Fas, role in *Helicobacter pylori*-induced apoptosis 651
thalidomide in inflammatory bowel disease 135
ischemic preconditioning in rat liver 1211
receptors, soluble; and interferon-g-inducing apoptosis, regulation of 1283
tumor
colorectal laterally spreading: clinical evaluation and endoscopic strategies updated (Letter to the Editor) 1344
gastrointestinal stromal cell; synchronous (Case Report) 1033
-infiltrating lymphocytes; Fas and Fas ligand interaction 32
primary hepatic carcinoid; with lymph node metastasis (Case Report) 1119
stain; prognostic factors of percutaneous ethanol injection 1205
suppressor genes; molecular pathology and gastric carcinoma 966
twins, monochorionic diamniotic monozygous; different hepatitis C virus transmission in 617

ulcer
bleeding; *Helicobacter pylori* and gastric ulcer angiogenesis 960
duodenal; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
gastric; roles of tumor necrosis factor-α-receptor type 1 and Fas in *Helicobacter pylori*-induced apoptosis 651
longitudinal; Behçet's colitis resembling Crohn's disease (Case Report) 105
marginal; endoscopic for a bleeding 1220
peptic
Helicobacter pylori and gastric ulcer angiogenesis 960
Helicobacter pylori in India 659
disease (Review) 488
ulcerative colitis
apoptosis in 758
development of despite long-term immunosuppression with cyclosporin and azathioprine in an Australian Aborigine (Letter to the Editor) 1130
Chlamydia pneumoniae and inflammatory bowel disease 987
effect of IS-741 on experimental colitis 854
Fusobacterium varium in 849

model; dysplasia–carcinoma in 1078
new therapies in inflammatory bowel disease S176
prebiotic treatment of (Review) 818
thalidomide in inflammatory bowel disease 135
ultrasonography
gallstone prevalence in Western Siberia 702
non-alcoholic and non-obese fatty liver 1098
urease; new formulation CLOtest 127
urge; colonic dsymotility in constipation 270
urinary trypsin inhibitor in acute liver failure 140
ursodeoxycholic acid
cytokines in primary biliary cirrhosis 196
efficacy of colestimide in cholestasis (Editorial) 1133
jejunal bile acid absorption 697

vaccination, DNA, against hepatitis E virus infection in cynomolgus macaques (Review) S365
vaccine; therapeutic vaccination in chronic hepatitis B 72
variability, genomic; hepatitis B viral genotypes 643
variant
chronic hepatitis B virus carriers and 'a' epitope variants 148
fibromellar; natural history of hepatocellular carcinoma (Review) 401
variation
genetic; hepatitis B surface gene (Editorial) 933
geographic; natural history of hepatocellular carcinoma (Review) 401
variceal
bleeding; rabbit model of non-cirrhotic portal fibrosis by immunosensitization 1312
hemorrhage; non-alcoholic steatohepatitis (Review) 526
ligation, endoscopic; non-alcoholic steatohepatitis (Review) 526
rupture; pathology of fundic varices 1064
varices
esophageal; management of bleeding in cirrhotic patients (Review) 355
fundic; pathology of 1064
gastric; management of bleeding in cirrhotic patients (Review) 355
vascular
damage; overlap of idiopathic portal hypertension and scleroderma (Case Report) 217
endothelial growth factor; interleukin-6 and angiogenic factor 1165
hindrance; volume restitution in portal hypertension 1317
lesions of the stomach (Images of Interest) 621
vasoconstrictors; hepatorenal syndrome in cirrhosis 739
vasopressin; drug therapy for acute bleeding in portal hypertensive gastropathy 973
vein
hepatic; granulomatous phlebitis (Case Report) 1334
obstruction, extrahepatic portal; non-alcoholic steatohepatitis (Review) 526
venules, regular arrangement of collecting; *Helicobacter pylori*-free stomach 39
villous adenomas, colorectal (Images of Interest) 1031
viral
dynamics and genotypes in hepatitis B virus, clinical relevance of (Review) S322
genotypes, hepatitis B (Editorial) 113
hepatitis; pediatric liver disease (Review) 521
pathogenesis of hepatocellular carcinoma (Review) S413
response, sustained
alanine aminotransferase in hepatitis C virus combination therapy 1307
hepatitis C advances in antiviral therapy (Review) 431
management issues in hepatitis C (Review) 415
virtual colonoscopy in Chinese 1323
virulence factor; nuclear factor-κB activation of *Helicobacter pylori* 556, 1244
viscosity; volume restitution in portal hypertension 1317
vitamin A; retinoids in hepatic fibrosis 791

water, fecal; fecal consistency in the Japanese population 1278
waves, in
large intestine, slow; ileo–ileal inhibitory reflex 1267
small intestine, electrical; ileo–ileal inhibitory reflex 1267
weight, fecal; fecal consistency in the Japanese population 1278

xanthine oxidase; role of oxyradicals in chronic pancreatitis 606

YMDD mutations during lamivudine therapy in patients with chronic hepatitis B, management of (Review) S333

zomepirac; hepatic covalent adduct formation 66